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A STUDY OF HOST GENETIC DETERMINANTS OF HUMAN 
PAPILLOMAVIRUS (HPV) INFECTION, CERVICAL CANCER 






Background: Cervical cancer, caused by oncogenic types of human papillomavirus 
(HPV), is the second most common cancer in women worldwide. Although large 
numbers of young sexually active women get HPV-infected only a small fraction 
develop cervical cancer pointing to co-factors including host genetics playing a role 
in the outcome of the disease. The aim of this thesis was to investigate the role of 
genetic polymorphisms in the cell death pathway genes, Fas (FasR-1377G/A and 
FasR-670A/G), FasL (FasL-844T/C) and CASP8 (CASP8 -652 6N ins/del) in 
cervical cancer, pre-cancers and HPV infection. The genes have also been 
investigated in herpes simplex virus type-2 (HSV-2) infection, a co-factor for 
developing cervical cancer. Another immune response gene, CCR2 (CCR2V64I) was 
also investigated. 
Materials: DNA from 1879 subjects comprising 447 women with cervical cancer 
(106 black African and 341 women of mixed-ancestry) and 1432 controls (306 black 
African and 1075 mixed-ancestry) matched in a 1:3 ratio to the cases on age, 
ethnicity and domicile status (urban/rural) was available.  265 HSV-2 infected and 













association. The ethical approval was obtained for this study from the University of 
Cape Town Research Ethics Committe (REC REF: 075/2009). 
Methods: The genomic DNA was extracted using TotalNucleicAcid Extraction kit 
and quantified using Nanodrop Spectrophotometer. Fas and FasL genotyping was 
carried out for 447 cases and 424 controls using TaqMan assaymix. 445 cases and 
1221 controls were genotyped for CASP8 using PCR-RFLP method. For CCR2 
genotyping PCR-SSP (sequence specific primers) method was using for 446 cases 
and 1432 controls by PCR-RFLP and PCR. Statistical analysis was done for the 
alleles, genotypes and haplotypes adjusted for ethnicity and smoking using R, 
haplo.stats, Stata 9 and Haploview 4.2 software. 
Results: The distribution of Fas and FasL polymorphisms were not different 
between cervical cancer patients and controls but were significantly different among 
black and mixed-ancestry women. However, the FasR-1377A allele was significantly 
associated with reduced risk of HSV-2 infection (OR (95% CI) = 0.58 (0.38-0.87), P 
= 0.008) . CASP8 -652 6N del/del genotype showed a significant association with 
increased risk of abnormal cytology (OR (95%CI) = 1.66 (1.00-2.75), P = 0.048) and 
with increased risk of high-risk HPV infection (OR (95%CI) = 2.84 (1.11-7.28), P = 
0.030) (only in black Africans) but no association with cervical cancer. The CCR2-
64I variant which is involved with the homing of macrophages was associated with 
increased risk of cervical cancer (OR (95%CI) = 6.14 (4.79-7.86), P = 0.001) and 
this significant susceptible effect was also present when squamous intraepithelial 
lesion (SIL) positive controls were compared to cervical cancer patients (OR 
(95%CI) = 6.86 (4.19-11.21), P = 0.001). 
Conclusion: This is the first study of the role of Fas, FasL, CASP8 and CCR2 













study reporting a non-HLA host genetic link to HSV-2 infection. Our results show 
that genetic polymorphisms in genes involved in the activation-induced cell death 
(AICD) are associated with differential risk to cervical cancer, pre-cancerous lesions, 
HPV infection and HSV-2 infection. We report that genetic variability in genes 
involved in macrophage recruitment is also associated with pre-cancerous lesions 















INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Cervical cancer  
 
1.1.1 Cervical Cancer burden in the world 
Cervical cancer is the second most frequent cancer and is a major cause of cancer 
related deaths in women worldwide. Approximately 493,243 new cervical cancer 
cases and 273,505 cervical cancer deaths were reported in 2007 (Castellsague X et 
al., 2007). The incidence of cervical cancer in most of Europe, North America, 
Australia and New Zealand is low at the present time due to effective screening 
programmes (Fig. 1.1) (Ferlay J et al., 2004) 
 
Fig. 1.1: Worlwide age-standardised incidence (per 100,000) of cervical cancer (Ferlay 













Before the introduction of screening programmes the incidence in these regions was 
much higher and similar to the high incidence rates of present day Africa. For 
example, at the time of the Second US National Cancer Survey in 1947 the age 
standardised incidence rate (ASIR) in the US was 38.0 in 10
5
 females (Dorn and 
CUTLER, 1959) which is much lower than the current ASIR of 15 per 100,000 in 
developed countries (Parkin and Bray, 2006). Effective screening programs have 
significantly reduced the incidence and mortality rates in developed countries. The 
lowest rates (ASIR = less than 15 per 100,000) are found in Europe, North America 
and Japan (Parkin and Bray, 2006). 
 
1.1.2 Cervical Cancer burden in southern Africa 
Due to poor screening programs and lack of treatment, 83% of all new cervical 
cancer cases and 85% of all cervical cancer-related deaths now occur in developing 
countries (Anorlu, 2008). Cervical cancer is the most common cancer with the 
highest cause of cancer mortality in women in sub-Saharan Africa. An estimated 
number of 70,700 new cases of invasive cervical cancer (ICC) occur each year which 
accounts for 25.4% of all cancers in women in sub-Saharan Africa (Parkin et al., 
2008). ICC incidence in sub-Saharan Africa is one of the highest in the world. The 
ASIR is estimated as 31 per 100,000 of sub-Saharan African women and varies by 
region with Southern Africa being 38.2 per 100,000 (Fig. 1.2) (Ferlay J et al., 

















Fig. 1.2: Age-standardised incidence rates of cervical cancer in Africa (Ferlay J et al., 
2004). 
 
Interestingly, the incidence rates remain unchanged in between 1960-1990 in South 
Africa (Parkin et al., 2008). It is projected that there will be 118,000 new ICC cases 
in 2025 in sub-Saharan Africa which is a 67% increase in the burden of cervical 
cancer compared to 2002 (Ferlay J et al., 2004). 
 
1.1.3 Classification and Stages of Cervical Cancer 
There are two main types of cervical cancer, squamous cell carcinoma and 
adenocarcinoma. Squamous cell carcinoma derives from squamous cells representing 
the majority of the cells in lower cervix and is the most common form of cervical 
cancer acquiring for 75% of all the cervical cancers. Adenocarcinoma arises from 
cervical glandular cells and is rarer (Vizcaino et al., 1998). Cervical cancer is a 
multistep process that develops progressively through different stages from normal 
epithelium to invasive cervical carcinoma following an HPV infection of oncogenic 
types (Paavonen, 2007). HPV infection may lead to atypical squamous cells of 













HPV in ASCUS leads to squamous intraepithelial lesions (SIL) (Rohan et al., 2003). 
SIL is further divided into low-grade (LSIL) and high-grade (HSIL) stages. LSIL are 
precancerous and are considered as very early precursor stages of cervical cancer 
that rarely progress to cancer (Snijders et al., 2006) while most HSILs progress to 
ICC when left untreated (Kobayashi et al., 2004). When HSIL penetrates the 
basement membrane and spreads to the other sites of the body it is called invasive 





Fig. 1.3: A schematic diagram showing the progression to ICC from normal epithelial 
cells by HPV infection. 
 
 
There is strong epidemiological and experimental data that have demonstrated a 
definite association of high-risk human papillomavirus (HR-HPV) infection and the 
development of cervical cancer (Schiffman et al., 1993;zur Hausen, 2002). HPVs are 
associated with > 99% of all cervical cancer cases worldwide (Fig. 1.5) (HPV 
Information Centre, 2009). The association of HPV with other cancers is much lower 

















Fig. 1.4: A schematic diagram showing the association of HPV with different types of 
cancers (HPV Information Centre, 2009) 
 
Two prophylactic HPV vaccines are currently available in the market, the bivalent 
vaccine for HPV 16 and 18 (Cervarix, GlaxoSmithKline Biologicals, Rixensart, 
Belgium) and the quadrivalent vaccine for HPV 6, 11, 16, and 18 (Gardasil, Merck 
and Co, Inc, Whitehouse Station, NJ, USA) (Cutts et al., 2007). The randomized 
controlled trials were performed for both the vaccines in over 60, 000 women prior 
to licensure and were assessed as safe and effective (Agorastos et al., 2009). Both the 
vaccines are prepared from non-infectious, DNA free virus-like particles produced 
by recombinant technology and show >90% protection against persisten HPV 
infection for upto 5 years. However, the vaccines can prevent HPV infection in 
relatively young women aged upto 26 years and not previously infected with the 
HPV subtypes covered by the vaccines (Cutts et al., 2007). Ongoing monitoring is 














Interestingly, although most sexually active women in the general population get 
infected by HPV, most of these cervical infections are transient, with clearance in 
70% to 90% of individuals positive for HPV DNA. In addition, only a small 
percentage develop long-term HPV infection, which is associated with an increased 
risk of developing cervical cancer. Thus, an effective host immune response may be 
an important determinant for the persistence and progression of HPV-induced 
cervical cancer. Variability in host immunogenetic
 
background is important in 
determining the overall cellular
 
immune response to HPV infections. Different 
environmental factors might also play a role in development of cancer of the cervix  
(Munoz et al., 2002;Parazzini et al., 1998;Plummer et al., 2003;Smith et al., 2003). 
 
1.2 Human Papillomavirus 
 
Papillomaviruses are widely distributed throughout the animal kingdom. These are 
small non-enveloped viruses with a double stranded DNA genome of approximately 
8000 bp (Fig. 1.5) (Doorbar, 2006). The genome consists of a long control region 
(LCR), an early region (E) and a late region (L). Different types differ by 10% in 
their sequences and sub-types differ by between 2% and 10% and variants differ by 
















Fig. 1.5: A schematic diagram showing the whole HPV genome (Doorbar, 2006) 
 
 
1.2.1 Human Papillomavirus types 
More than 100 different HPV genotypes have been fully cloned and sequenced 
(Stoler, 2000) and the origin of the virus is estimated to be before the devepoment of 
Homo sapiens (Ong et al., 1993). Oncogenic HPVs are the cause of more than 99% 
of all cervical cancer cases. The association of HPV‟s with cervical lesions have led 
to a classification of the virus as „low-risk‟ and „high-risk‟ strains; the persistence of 
infection by high risk strains being associated with higher risk for abnormal pap 
smear (Ho et al., 1998) and invasive carcinoma (Wallin et al., 1999). HPV 6, 11, 40, 
42, 43, 44, 54, 61, 70, 72 and 81 are low-risk viruses and HPV 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 68, 73, and 82 are high-risk viruses (Cogliano et al., 
2005;Munoz et al., 2003). The five most frequent HPV types among women with 













the five most frequent types in sub-Saharan African women in ranking order are, 
HPV 16, 18, 45, 33 and 35 (HPV Information Centre, 2009). HPV 16 is predominant 
in squamous cell carcinomas and HPV 18 in adenocarcinomas. HPV 16 and 18 
constitute 70.1% of all the invasive cervical cancer cases across the globe 
(Castellsague X et al., 2007). 
 
1.2.2 Human Papillomavirus infective cycle and host immune evasion 
HPV infects basal keratinocytes of epithelium. Once HPV penetrates inside the cell, 




Fig. 1.6: A schematic diagram showing the infective cycle of HPV (Stanley, 2008) 
 
The HPV genome incorporates into the host cell and becomes established as extra-
chromosomal elements in the nucleus of the cell and the copy number is increased to 
50-100 copies per cell (Paavonen, 2007). As the infected basal cells differentiate and 
mature, the HPV genome replicates too and the viral DNA is passed on to both 
daughter cells. One daughter cell migrates away from basal layer and initiates a 
programme of differentiation while the other one continues to divide in the basal 













proteins. The early proteins E6 and E7 immortalise epithelial cells (Halbert et al., 
1991;Hawley-Nelson et al., 1989) and promote cell proliferation. This delays natural 
maturation and differentiation of epithelial cells so as to give the virus time to 
expand the infection and spread to adjacent cells. While E6 and E7 genes are 
consistently expressed the other viral gene expressions are disturbed (Baker et al., 
1987). At this stage the virus exploits the host cell‟s transcriptional machinery to 
synthesize its late proteins L1 and L2 which help the newly formed virus to assemble 
(Paavonen, 2007). Once an infection is established in the basal cells the virus moves 
within differentiating cells to the epithelial surface and is shed off and is available to 
spread. As a result of disrupted cell division, infected epithelial cells outgrow non-
infected cells resulting in a dysplasia or tumor. It is speculated that HPV spread to a 
new host by direct skin contact, possibly within days of viral particle formation. 
 
The integration of the HPV genome into the host cell chromosome is an important 
event in the development of cervical cancer from pre-cancerous lesions. Changes in 
the expression of HPV genes at the integration sites may participate in cancer 
development (Yu et al., 2005). Integration often results in loss of E2 and 
deregulation of E6 and E7 expression (Doorbar, 2006). These are critical events for 
the growth of cervical cancer cells. Due to the less differentiated cells, viral genome 
amplification occurs closer to the epithelial surface in HSIL compared to in 
condylomas and LSIL. For the same reason the expression of the viral coat protein is 
also retarded in HSIL (Middleton et al., 2003). Integrated HPV DNA is found in 
most invasive cancers, high-grade lesions but can also be found in some CIN1 
lesions (Fujii et al., 2005). The high-risk HPV  E7 protein acts more efficiently than 













round of cell division (Duensing and Munger, 2004). The high-risk HPV E6 proteins 
bind to p53 with a better affinity than the low-risk E6 protein and stimulate p53 
degradation (Huibregtse et al., 1993). The loss of p53-mediated DNA damage 
response is one of the most important molecular mechanisms that leads to cervical 
cancer. Additional genetic changes accumulated over a period of time following the 
initial HPV infection speeds up the development of the cancer of the cervix. 
 
Cervical carcinoma is accompanied by genomic instability and choromosomal 
aberrations. While low-risk HPV E6/E7 proteins are not capable of inducing 
centrosome abnormalities, high-risk HPV E6/E7 proteins can induce centrosome 
abnormalities and cause genomic instability (White et al., 1994). The key function of 
HPV E6 and E7 proteins is to cause inactivation of the p53 and pRB tumour 
suppressor pathways consecutively. Inactivation of p53 by E6 protein suppresses two 
major events, 1) Cell growth arrest in G1 phase followed by DNA repair and 2) 
Apoptosis, resulting in DNA damage and survival of infected cells (Linke et al., 
1996). The pRB protein acts as a break point for cells progressing into S-phase. 
Inactivation of pRB allows tumour cells to enter into S-phase leading to cell 
replication (Dyson et al., 1989). 
 
1.3 Immune response to Human Papillomavirus 
 
The human defense against pathogenic micro-organisms can be divided into early 















1.3.1 Innate immune response to Human Papillomavirus 
This is the primary and rapid response of the body to a foreign microbe. Physical and 
chemical barriers like epithelia, phagocytic cells like macrophages and neutrophils, 
natural killer (NK) cells, blood proteins including complements and cytokines are the 
main components of this immune reaction (Bruce A et al., 2002). 
 
During most of the HPV infectious cycle, a wide range of different cytokines, 
important for dendritic cell (DC) activation and migration and essential signal to kick 
start the immune response in squamous epithelia such as proinflammatory cytokines, 
growth factors and chemokines are secreted in low levels by cervical keratinocytes 
(Stanley et al., 2007). A vital cytokine tumour necrosis factor (TNF) shows a direct 
antiviral and antiproliferative effect. Apoptosis of the HPV-infected cells and 
spontaneous regression of papillomas correlate with high levels of expression of 
TNF-α in infiltrating mononuclear cells (Hagari et al., 1995). TNF-α and another 
antiviral cytokine interleukin (IL)-1 have both shown an ability to downregulate 
HPV E6 and E7 gene expression and retard the growth of cell lines harboring the 
viral genome (Kyo et al., 1994). HPV-infected keratinocytes activate the powerful 
antiviral defence system of type 1 Interferons (IFNs) consisting of IFN-α, -β and -γ. 
The type 1 IFNs have antiviral, antiproliferative, anti-angiogenic and 
immnostimulatory properties that act as a bridge between innate and adaptive 
immunity and also acrtivates immature DCs (Le and Tough, 2002). High-risk HPV 
infection down-regulates IFN-α mediated gene expression and the HPV E6 and E7 
oncoproteins interferes directly with IFN signalling pathways (Woodworth, 2002). 
HPV E6 and E7 proteins bind to interferon regulatory factor-3 (IRF-3) and IRF-1 













1995;Ronco et al., 1998). NK cells are important components of the innate immune 
response to HPV infections. NK cells are a sub-set of lymphocytes that kill virus-
infected or tumour cells that lack surface expression of MHC class I molecules 
(Stanley, 2009). 
 
1.3.2 Adaptive immune response to Human Papillomavirus  
Adaptive immunity consists of humoral immunity and cell-mediated immunity 
(CMI). Humoral immunity is mediated by B-lymphocytes and CMI is mediated by 
T-lymphocytes. 
 
Humoral immunity is mediated by antibodies (Abs) or immunoglobulins produced 
by B-lymphocytes. Abs are freely circulating in blood and are the principal defence 
against extracellular microbes. They bind to the foreign particles and help to 
eliminate them. Abs recognise viral particles in early stages of HPV infection, even 
though the humoral immune system is not always activated by natural HPV 
infection. Abs can also neutralize viral particles by binding to their receptors. IgG 
abs which are specific for HPV epitopes can protect against infection with oncogenic 
HPV (Nardelli-Haefliger et al., 2003). Studies have shown that higher levels of 
serum IgG is capable of neutralizing HPV (Nardelli-Haefliger et al., 2003). IgG 
responses can also promote limited cross-neutralization and cross-protection from 
different oncogenic HPV types (Einstein, 2008). 
 
Antigen presenting cells (APCs) display antigens derived from intracellular 
microbes, which are recognised by these cells. The genes in Major 













presentation. Human MHCs are called Human Leukocyte Antigens (HLAs) and are 
highly important in inducing effective immune-response against any invading 
antigens. The HLA genes are localized on chromosome 6. The extraordinary 
polymorphism of HLA genes suggests „overdominant selection‟ or „heterozygous 
advantage‟, presented by individuals heterozygous at HLA loci. A greater variety of 
antigenic peptides against the invading pathogenic micro-organisms are processed by 
heterozygotes compared to homozygotes. The highly polymorphic nature of HLAs 
helps to bind a wide variety of foreign antigenic peptides by heterozygotes compared 
to homozygotes resulting in protection against different pathogenic microbes. This 
results in a more efficient immune response against a wide range of pathogens 
(Doherty and Zinkernagel, 1975;Zinkernagel, 1996). Langerhans cells (LHc) are 
immature dendritic cells and the resident APC in many epithelial sites of the body, 
including the cervix. APCs capture antigens and transport them to local lymph nodes 
where a T-cell response is activated. Studies have reported a reduced number of LHc 
in genital HPV infection and in SIL (Morelli et al., 1994;Morris et al., 1983;Tay et 
al., 1987). After capturing antigens the LHc migrate to draining lymph nodes. 
Cytokines mainly produced by keratinocytes play a helping role in LHc function. IL 
1-α, TNF and IL 1-β which activate and promote LHc migration and IL-10 which 
inhibits LHc migration have been particularly important (Wang et al., 1999). 
Keratinocytes in normal cervix express TNF-α but low-grade and high grade 
squamous intraepithelial lesions (LSIL and HSIL) have shown an absence of TNF-α 
expression (Mota et al., 1999). Cytokine IL-10 was also found absent in normal 















CMI is mediated by T-lymphocytes which can be classified as CD4+ helper T-
lymphocytes and CD8+ cytotoxic T-lymphocytes (CTLs). CD4+ helper T cells can 
be divided into TH1 and TH2 cells. TH1 cells stimulate responses from 
macrophages, NK cells and CD8+ CTLs especially during infections of intracellular 
microbes. The signature cytokine of TH1 cells is IFN- γ but they also produce TNF 
and IL-2. Many studies suggest that HPV infection triggers a TH1 response. The 
signature cytokines of TH2 cells are IL-4 and IL-5 but they also produce IL-10 and 
IL-13 (Mosmann and Sad, 1996). TH2 cells mostly activate humoral immunity. 
Studies have found low density of TH1 cells and high density of TH2 cells in HSIL 
compared to normal epithelium (Al-Saleh et al., 1998). It has been shown that HPV 
specific CD4+ cells in lymph nodes of cervical cancer patients produce IL-10 and 
suppress HPV specific cell mediated immunity which gives an explanation for a 
failed HPV specific CD4+ immunity in cervical cancer patients (van der Burg SH et 
al., 2005). Even though HPV generally elicits a TH1 response, a shift toward TH2 
response is associated with HPV linked cervical pathology. 
 
Cytotoxic T Lymphocytes (CTLs) are CD8+ cells that recognise specific viral 
antigens (or more accurately a small part of the antigen called, “epitope”)  and kill 
virus infected cells by releasing cytotoxins and cytokines. The CTLs control tumour 
cells through two major pathways, the cell death pathway (Fas-FasL) and the granule 
secretory pathway. Apoptosis can be induced by any of these pathways. The 
activation of Fas-FasL cell death pathway in induction of apoptosis is described in 
detail later in this section.Apoptosis induced by the granule exocytosis pathway is 
regulated by Perforin (PFN) and granzyme (gzm) molecules. Once a target cell is 













and fuse with the plasma membrane releasing granule contents. These granules 
diffuse toward the target cell and granzymes are delivered which is facilitated by 
perforin. Granzymes are encoded by five gzm genes in humans namely, gzmA, gzmB, 
gzmK, gzmH and gzmM. PFN plays a critical role with gzmA and gzmB in the 
control of viral infections (Russell and Ley, 2002). However, their importance in 
eliminating tumour cells is poorly understood (Revell et al., 2005). The 
understanding of the biological roles played by other gzms, termed as orphan gzms 
(gzmC-G, gzmK, gzmL, gzmN and gzmM) is also not clear. 
 
Apotosis in virus infected cells is induced by gzmA (Hayes et al., 1989) and gzmB 
(Shi et al., 1992) in presence of PRF. Studies with ex vivo derived Tc cells from 
gzmKO mice showed impaired apoptosis in the absence of gzmB and more so in the 
absence of both gzmA and gzmB (Pardo et al., 2002). The perforin/granzyme 
pathway plays an important role in controlling HPV infection. In vitro Studies have 
shown increased anti-tumour activity of HPV E-7 specific CTLs (Sin et al., 2009) in 
destruction of HPV infected keratinocytes. 
 
Activated CTL and HPV 16 E6 and E7 specific CTL have been found in SIL and 
HPV specific CTL in individuals with a previous or ongoing HPV infection 
(Alexander et al., 1996;Bontkes et al., 1997;Evans et al., 1996;Evans et al., 
1997;Nakagawa et al., 1997). A longitudinal study of women with HPV 16 infection 
showed lack of CTL response to HPV E6 but not to HPV E7 protein correlated with 
persistent HPV infection, suggesting that a CTL response to HPV 16 E6 protein is 
important for the clearance of HPV and for neoplastic progression (Nakagawa et al., 













helper T-cells help to maintain antiviral CD8+ T-cell activity for the generation of 
strong virus neutralising Abs. 
 
1.4 Environmental risk factors 
 
Along with high-risk HPV infection there are some additional risk factors that have 
been studied and have been reported to play an important role in the outcome of 
cervical cancer. Studies have indicated cervical dysplasia, smoking (Plummer et al., 
2003), high parity (Munoz et al., 2002) and long term use of oral contraceptives 
(Moreno et al., 2002;Smith et al., 2003) and high number of sexual partners as the 
risk factors for persistent HPV infection. Co-infection with other sexually 
transmitted agents such as Herpes Simplex Virus-2 (HSV-2) (Castellsague et al., 
2006;Hildesheim et al., 1991;Smith et al., 2002) might also add to the risk. 
 
1.5 Role of host genetic risk factors in cancer 
 
Cancer can be termed a class of diseases where the main feature is uncontrolled cell 
growth due to genetic abnormalities occurring either on cancer suppressing and 
cancer promoting genes. Genetic changes in regulatory mechanisms alter normal cell 
behaviour and cause cellular abnormality (Kinzler WK and Bert V, 2002). There are 
3 major classes of genes affecting carcinogenesis; tumour suppressor genes, 
oncogenes and DNA repair genes. Tumour suppressor genes inhibit cellular 
uncontrolled cell proliferation while oncogenes, such as growth and transcription 
factor genes (like HA-RAS) generally promote cell proliferation. Mutations in these 













normal circumstances cells possess mechanisms (e.g DNA repair genes) to maintain 
the genome in areas where mutations have occurred thereby restoring the cells to 
their normal genotype or programming them to apoptose and get removed from the 
system. A driving force of tumour development is genetic instability i.e. higher 
frequency of mutations. The genetic instability can be caused by defects in DNA 
repair systems which are a result of mutations in DNA repair genes. As apoptosis is 
an important factor for regulating uncontrolled cellular growth, abberant functioning 
of genes involved in apoptotic pathways (e.g. Fas, FasL) can lead to cancer 
development. Genes encoding cytokine proteins (like, TNF, IL, IFN) play a crucial 
immunological role in protection against pathogenic microbes and are of particular 
interest for viral infection leading to cancer. Human leukocyte antigen (HLA) genes 
are also important in determining host immune response to pathogenic organisms 
due to their highly polymorphic nature. Almost all cancers are caused by 
abnormalities in the genetic material that can be due to randomly acquired errors in 
DNA replication or inherited (Croce, 2008). 
 
1.6 Host genetic risk factors for cervical cancer 
 
The genetic link to cervical cancer development is supported by epidemiological 
studies. A hereditary component of cervical tumours has been indentified by the  
comparisons of twins (Ahlbom et al., 1997) and in a mother-daughter family studies 
(Hemminki et al., 1999). The possibility of host genetic predisposition is 
strengthened by the observation that biological first degree relatives of a woman who 
has developed cervical tumour, experience a two-fold risk of developing cervical 













(Magnusson et al., 1999). The heritability of cervical tumours have been determined 
as 27% (Magnusson et al., 2000). 
 
Three different strategies can be used for genetic studies of human complex diseases, 1) 
Family studies, 2) Animal models and 3) Case-control studies. As it is difficult to find 
families or relatives affected by the same disease and also to find animal models, case-
control studies are hugely popular and are mostly carried out by researchers for the genetic 
studies of different complex diseases. 
 
There are two main approaches for investigating the genetic associations of complex 
and quantitative traits, genome-wide scan and candidate gene approach. Each of 
these approaches has specific advantages and disadvantages. Genome-wide scan is a 
method to search the entire human genome to find the causative genetic associations 
for a particular disease. This is done without any presumptions of the importance of 
functional features of the trait under investigation. Several DNA markers are used in 
family-based or experimental based designs on a large number of candidate genes. 
The main disadvantage of this method is the sheer expense the intensive resources to 
carry out the work. The candidate gene approach is based on the existing knowledge 
from the literature. The candidate genes are generally the genes with known 
biological function directly or indirectly affecting the trait under investigation. This 
approach is comparatively less expensive and can be done with limited number of 
resources (Zhu and Zhao, 2007). Due to these advantages candidate gene approach is 
highly popular and has been extensively applied for gene-disease research, genetic 
association studies, biomarker and drug target selection in different organisms from 
animal to humans (Tabor et al., 2002). The main limitation of traditional candidate 













phenotype. Low replication of results and its limited ability to include all possible 
causative genes are other disadvantages of this approach (Tabor et al., 2002). 
 
Candidate gene approach was adapted for the present investigation mainly due to 
the well known biology of persistent HPV infection and cervical cancer. The host 
genetic association studies with cervical cancer in different population led us to a 
better understanding of the pathways to be investigated. The lack of host genetic 
association studies with cervical cancer in African population had set a good 
platform for a candidate gene approach to investigate the host genetic associations 
of cervical cancer. 
 
Several different candidate genes have been investigated by different groups across 
the globe. Some of the major host genes known to influence the outcome of the 
disease (other than the candidate genes investigated in this thesis which will be 
discussed in detail later in this chapter) are reviewed below. 
 
HLA DQ and DR genes have been extensively studied by many groups in different 
population across the globe. DQA1*01, *03 and DQB1*02, *03, *04, *06 alleles 
have been associated with increased risk of developing the disease. A protective 
association has also been found with DQA1*0501 and DQB1*0201, *0103, 
*0301/*0501, *04, *05, *050201, *06 alleles. A protective effect of the DRB1 
*13/DQB1 *0603 had been the most consistent HLA findings of all (Hildesheim 














The Tp53 codon-72 (Arg/Pro) polymorphism was first investigated by Storey et. al.  
in cervical cancer patients (Storey et al., 1998). They reported a seven times higher 
risk of developing HPV-associated cervical carcinogenesis in individuals with Arg 
homozygosity. Many publications investigating the Tp53 codon-72 polymorphism 
in cervical cancer susceptibility in different ethnic groups followed with 
contradictory results (Jee et al., 2004). 
 
Tumour Necrosis Factor (TNF) is a cytokine and is produced mainly by activated 
macrophages. Several polymorphic sites have been reported in TNF locus 
including five microsatellites of TNFa-e. TNF-a is closely linked to TNF-β gene 
and contains 14 different alleles (a1-a14) with an AC/GT dinucelotide repeat. 
Several groups investigated the role of various polymorphic sites of TNF gene in 
association to cervical cancer in different ethnic populations. A positive association 
was found with cervical cancer and the presence of TNFa-8, TNF-α -572, -857, -
863 and also with TNF G-308A (Zoodsma et al., 2005). TNFG-308A did not show 
any association in South African population (Govan et al., 2006). 
 
MHC class I polypeptide-related sequence A or MICA genes are expressed by 
keratinocytes and epithelial cells on the cell surface and interacts with T cells with 
an important role in immune response and direct induction of mucosal immunity. 
Exon 5 of MICA gene contains a microsatellite locus with 5 alleles, in strong 
linkage disequilibrium with HLA-B alleles. Different polymorphic sites of MICA 
were investigated but none were found to have an association with the severity of 














Any changes in WAF1/p21 gene may affect the regulation of cell growth and 
result in excessive proliferation of cancer cells. A serine to arginine change has 
been well documented followed by a C to A transversion at the third base of 
codon 31. Different groups studied this polymorphism with mixed results. 
Ser/Ser genotype was found to be the susceptible genotype for adenocarcinoma 
in high risk HPV but not for squamous cell carcinoma. Ser/Arg genotype was 
associated with susceptibility to cervical cancer (Zoodsma et al., 2005). 
 
IL-10 is a TH2 type cytokine produces a suppressive effect on cell mediated 
immunity. One of the polymorphisms that is associated with low, medium or 
high production of IL-10 situates in the promoter region of the gene at position -
1082. Several studies investigated this polymorphism and reported conflicting 
results. -1082 A/G was found to be the risk genotype for cervical cancer 
(Zoodsma et al., 2005). 
 
Methylenetetrahydrofolate reductase or MTHFR enzyme regulates the 
metabolism of folate and methionine, which are critical for DNA methylation 
and synthesis. C to T transition at nucleotide position 677 of the MTHFR gene 
results in alanine to valine. Compared to homozygous wild type (Ala/Ala), both 
heterozygous (Ala/Val) and homozygous mutant (Val/Val) variants reduce 
MTHFR enzyme activity in individuals with a low folate status. Hence this 
polymorphism might cause an abnormal DNA methylation and DNA synthesis 
which can lead to an increased risk of developing cancer. This polymorphism is 
less frequent in blacks than in Caucasians. Different groups investigated the 













found by different groups. Some found the polymorphism as a risk factor to 
develop cervical cancer while others did not (Zoodsma et al., 2005). 
 
1.7 Genes investigated in this thesis 
 
In this thesis we are focusing on the common polymorphisms in some of the major 
host genes with important immunological functions. Three genes in the cell death 
pathway, namely Fas, FasL and CASP8 and an inflammatory pathway gene CCR2 
were focused on for this thesis. The effects of the common polymorphisms on these 
four genes on susceptibility to infection with HPV leading to cervical cancer and 
HSV-2 infection were investigated.  
 
1.8 Fas and Fas Ligand (FasL) genes and their roles in immune 
response 
 
The Fas gene is situated on chromosome 10q24.1 and the FasL on 1q23. Fas and 
FasL are two crucial genes on the cell death pathway. Fas is a cell-surface death 
receptor also called CD95. Binding of the Fas receptor (FasR) with FasL triggers 
expression of caspase-8, which in turn signals the cells to initiate apoptosis (Fig. 1.7) 
















Fig. 1.7: Activation of Fas-FasL pathway (Cotran RS et al., 1999) 
 
Apoptosis is a highly regulated process of cell suicide, also called as programmed 
cell death. The role of corrupted apoptosis has been well documented in the 
development of tumorigenesis, a process by which normal cells transform into 
tumour cells. Tumorigenesis is achieved not only by increased cell proliferation but 
also by a decreased apoptotic rate (Zornig et al., 2001). Defects in genes that paly a 
role in the mechanism of apoptosis such as Fas and FasL has been identified as 
cancer causing event.   
 
The signal produced by the DNA binding of transcription factors SP1 (stimulatory 
protein 1) and STAT1 (signal transducer and activator of transcription 1) are 
associated with transcriptional activation and expression of Fas gene. Fas -1377 G>A 
and -670 A>G are situated within SP1 and STAT1 binding sites respectively. It has 
been shown that the substitution of G by A at position -1377 of the Fas promoter 
region considerably reduces SP1 binding (Huang et al., 1997;Sibley et al., 2003) thus 
affecting the regulation of apoptosis. Gamma interferon activation signal (GAS) is a 













within GAS binding site. The presence of G at position -670 in the Fas promoter 
region partially or completely abolishes the GAS element, hence significantly 
reducing the Fas gene expression (Huang et al., 1997;Kanemitsu et al., 2002;Sibley 
et al., 2003) which results in decreased activation induced cell death (AICD) of 
virus-infected target cells leading to uncontrolled growth of the virus. It has also 
been shown that a higher basal expression of FasL is associated with the C allele at 
position 844 of the  FasL gene (Wu et al., 2003). Reduced expression of FasL 
inhibits the apoptotic activity of the Fas-FasL pathway.  
 
These Fas and FasL polymorphisms that impair the apoptotic signals have been 
associated with susceptibility to a number of different cancers such as, malignant 
lymphomas, lymphoproliferative syndrome, T-cell lymphoma, Hodgkin‟s disease, 
urinary bladder cancer, lung cancer, esophageal squamous-cell cancer (Davidson et 
al., 1998;Lee et al., 1999;Peters et al., 1999;Sun et al., 2004;Takahashi et al., 
1994;Zhang et al., 2005), and cervical cancer (Dybikowska et al., 2004;Engelmark et 
al., 2004;Ivansson et al., 2007a;Lai et al., 2003;Lai et al., 2005;Sun et al., 2005). Six 
studies have shown conflicting results on the role of Fas and FasL polymorphisms 
but this could be due to the fact that the studies were done in different populations. In 
one group the FasR-670A allele and A/A genotype were associated with higher risk 
of developing cervical cancer (Lai et al., 2003). The same group replicated the 
results for FasR-670 in another case-control study (Lai et al., 2005) and reported no 
role for Fas-1377 G→A or FasL844 T→C polymorphisms with disease severity. 
Two other groups found different results for FasR-670, in a case control study 
(Dybikowska et al., 2004) and in an affected sib-pair (ASP) study (Engelmark et al., 













Swedish subjects (Ivansson et al., 2007a), respectively, reported an association of 
FasL844C allele and FasL-844C/C genotype with susceptibility to cervical cancer. 
 
Fas and FasL can be expressed in a variety of normal human tissues. Although some 
studies investigated the correlation of Fas and FasL expression between malignant 
and normal tissues, the results are still not clear (Jiang et al., 2002). A recent study 
showed Fas expression in cytomembrane (CM), cytoplasm and cytoblasts. Fas was 
basically expressed in four target cells, gastric epithelial cells (GECs), gastric 
carcinoma cells (GCCs), normal gastric stroma-infiltrating lymphoid cells (NGILs) 
and tumour-infiltrating lymphoid cells (TILs). The expression of Fas was 
significantly higher in GECs compared to GCCs and in TILs compared to NGILs 
(Liu et al., 2009). The FasL was also expressed on the CM, cytoplasm and 
cytoblasts. FasL expression was seen in all the four target cells like Fas, GECs, 
GCCs, NGILs and TILs. There was no significant difference in FasL expression 
between GECs and GCCs or NGILs and TILs (Liu et al., 2009). 
 
1.9 CASP8 gene and its role in immune response 
 
The CASP8 gene is localized on chromosome 2q33 and codes for Caspase 8 protein 
which is involved in initiating apoptosis. This gene is also known as, FLICE or 
MCH5. Various caspases are found downstream of Fas and FasL, among which 
caspase-8 plays one of the most important roles in generating apoptotic signals 
(Siegel, 2006). It is central in activating a caspase-cascade receiving apoptotic 
signals from Fas-FasL interaction which triggers apoptosis (Ju et al., 1995). 













receptor (extrinsic) and the mitochondrial (intrinsic) pathway (Fulda and Debatin, 
2006). Stimulation of any of the pathways can lead to the activation of caspases 
(Degterev et al., 2003). Apoptosis, one of the most crucial functions of the human 
immune system to control tumours by eliminating potentially malignant cells is a 
form of programmed cell death to maintain homeostasis in many tissues (Evan and 
Vousden, 2001). Apoptosis is a mechanism of restricting uncontrolled growth of 
cells. Thus reduced apoptosis would lead to cancer formation and progression (Lowe 
and Lin, 2000). One of the main characteristics of cancer is to bypass apoptosis by 
forcing the cell to ignore the apoptotic signals that in a normal circumstance would 
lead to cell suicide (Hanahan and Weinberg, 2000). Signals generated by the 
interaction of cell-surface death receptor Fas together with Fas ligand (FasL) 
activates caspase leading to apoptosis (Fig. 1.8) (Harvey Lodish, 2003;Siegel, 
2006;Suda et al., 1993).  
 
 The expression and activities of caspases have been shown by several studies as one 
of the most important factors for survival of immune cells and have also been 
associated with many pathological conditions including cancer (Siegel, 2006). Apart 
from apoptosis caspase-8 also has various other functions such as controlling T cell 
proliferation (geciras-Schimnich et al., 2002;Launay et al., 2005) and differentiation 

















Fig. 1.8: A detailed diagram showing the activation of Caspase-8 through Fas-FasL 
pathway (Harvey Lodish, 2003) 
 
 
Subcellular localization of active caspase-8 may control either proliferation or 
apoptosis (Koenig et al., 2008). Polymorphic variations in CASP8 gene might result 
in differential expressions of caspase-8 leading to altered apoptosis and eventually 
influence the tumour progression and susceptibility to cancer. 
 
Two commonly known polymorphisms in the CASP8 gene have been well studied, 
namely CASP8 D302H and CASP8 -652 6N ins/del (Sergentanis and 
Economopoulos, 2009). A functional polymorphism of a six nucleotide deletion of 













652 6N ins/del) has been identified. This six nucleotide deletion destroys a binding 
element for transcriptional activator stimulatory protein-1 (SP1) which decreases 
capase-8 expression leading to reduced apoptosis (Sun et al., 2007). This 
polymorphism has been associated with several pathological conditions including 
multiple types of cancers including cervical cancer (Cybulski et al., 2008;De et al., 
2009;Frank et al., 2008;Ji et al., 2009;Li et al., 2008;Ni et al., 2009;Pittman et al., 
2008;Sun et al., 2007;Wang et al., 2009;Yang et al., 2008). CASP8 -652 6N del/del 
genotype was shown to reduce the risk of lung cancer, esophageal cancer, gastric 
cancer, breast cancer and colorectal cancer in a Chinese population (Sun et al., 
2007). Studies among Germans (Frank et al., 2008), Polish (Cybulski et al., 2008) 
and Italian subjects (De et al., 2009) did not find any association of this variant with 
breast cancer risk. However, this variant was associated with later age at diagnosis 
for breast cancer in Italian population (De et al., 2009). The association with 
colorectal cancer was also not found in a British population (Pittman et al., 2008). 
CASP8 -652 6N del/del genotype was reported to decrease the risk of cutaneous 
melanoma in an American population (Li et al., 2008) and pancreatic (Yang et al., 
2008) and bladder cancer (Wang et al., 2009) in Chinese population. The variant had 
no effect on prostate cancer in a Polish population (Cybulski et al., 2008). CASP8 -
652 6N del/del genotype has also been associated with decreased sperm apoptosis 
and poor sperm motility (Ji et al., 2009) and with increased risk of Coal Worker‟s 
Pneumoconiosis (Ni et al., 2009) in Chinese population. 
 
Only one study investigated the influence of CASP8 polymorphism on development 













ins/del polymorphism in a Chinese population and reported a reduced risk of 
developing cervical cancer with CASP8 -652 6N del/del (Sun et al., 2007). 
 
1.10 Chemokine receptor-2 (CCR2) gene and its role in immune 
response 
CCR2 gene is situated on chromosome 3p21. One of the earliest responses of human 
body to injury or infection is the release of chemokines that triggers penetration of 




Fig 1.9: A diagram showing chemokine activation following inflammation and 














Chemokines are chemoattractant cytokines that regulate migration of leukocytes by 
binding to G-protein coupled cell-surface receptors. It has been postulated that HPV 
disrupts the interaction between epithelial cells and the immune system by 
deregulating the expression of chemokines, mediated by (HPV) E7 that interacts 
with IRF-1 (Gerard and Rollins, 2001) which have been associated with bacterial or 
viral infections, autoimmune diseases, heart diseases and many others (Gerard and 
Rollins, 2001). Chemokine receptor 2 or CCR2, has affinity for CCL2 (monocyte 
chemoattractant protein-1 (MCP-1)), CCL7, CCL8 and CCL13 ligands and is 
expressed on basophils, monocytes, dendritic cells, activated T-cells and NK cells. 
CCR2 is a major  receptor for the MCP-1 which is produced largely by tumour cells 
(Kurihara et al., 1997;MacKay, 2001) and is responsible for recruiting macrophages 
to tumors in bladder, cervix, ovary, lung and breast. The role of macrophages in 
tumour development and control is multifactorial. In early stages, macrophages have 
tumour cytotoxic characteristics but once tumour cells have evaded the immune 
system, the macrophages, switch to play a role in tumour angiogenesis (Lamagna et 
al., 2006;Lin and Pollard, 2007;Vicari and Caux, 2002). Though macrophages 
display tumor cytotoxicity, tumor-associated macrophages (TAMs) mainly have 
protumor functions (Mantovani et al., 1992) and help in tumor angiogenesis. More 
expression of MCP-1 recruits more macrophages and speeds up the process of tumor 
progression. It was shown that 1/6 high grade squamous intraepithelial neoplasia 
expressed MCP-1 compared to 4/5 squamous cell cervical caracinomas (Riethdorf et 
al., 1996) suggesting that MCP-1 plays a greater role in invasive cancers compared 
to pre-cancers. This was further confirmed by in situ hybrisation studies (Kleine-
Lowinski et al., 1999) where MCP-1 mRNA expression was detected in the stroma 













reported with high levels of MCP-1 expression (Kleine-Lowinski et al., 1999). 
Macrophages which are recruited by MCP-1 chemokine, express CCR2 on their cell-
surface. 
 
CCR2 has two isoforms – CCR2A and CCR2B originated from the CCR2 gene by 
alternative splicing. A single nucleotide polymorphism (SNP) of G to A at position 
190 of CCR2 gene changes amino acid valine (GTC) to isoleucine (ATC) at codon 
64 (CCR2-V64I). This conservative amino acid change takes place in the first 
transmembrane domain of CCR2A and CCR2B. This change makes CCR2A more 
stable and increases its half-life but does not any way affect the stability of CCR2B 
isoform. The increased stability of CCR2A might lead to accumulation of a large 
amount of this isoform on the macrophage cell-surface which also interferes with the 
CCR2B function. This misleads the cells and the macrophage recruitment drops 
during the development of the tumor which hampers the tumor angiogenesis and 
eventually reduces the risk of progression to tumour. 
 
This polymorphism (CCR2-V64I) has been extensively studied and several reports 
show a protective role of the polymorphism with AIDS (Doms and Peiper, 
1997;Ioannidis et al., 2001;Mulherin et al., 2003;Smith et al., 1997), multiple 
sclerosis (Miyagishi et al., 2003) and breast cancer (Zafiropoulos et al., 2004). It is 
also associated with increased risk of carotid atherosclerosis (Nyquist et al., 2009) 
and reduction in the risk of renal transplant rejection (Omrani et al., 2008). There are 
conflicting reports on the role of the CCR2-V64I polymorphism in the development 
or risk of cervical cancer (Coelho et al., 2005;Coelho et al., 2007;Ivansson et al., 













Portuguese population reported that the CCR2-64I variant was associated with 
reduced risk of developing ICC from HSIL (Coelho et al., 2005). The same group 
conducted a case-control study in the same population comparing women with HSIL 
to a control group and found the CCR2-64I variant was a risk allele for developing 
HSIL (Coelho et al., 2007). Among two studies in Swedish populations, the first 
study (Ivansson et al., 2007a) reported that the CCR2-64I variant of this SNP was 
associated with decreased risk of developing cervical cancer. The second Swedish 
study did not find any association of CCR2-64I variant with either HPV infection or 
cancer of the cervix (Zheng et al., 2006). 
 
1.11 Host genetic studies of cervical cancer in Africa 
 
Most of the host genetic studies of cervical cancer have been done with Caucasian 
population. Only a handful of studies have been done in Africa (Stanczuk et al., 
2001;Stanczuk et al., 2003;Tanara et al., 2003). The IL-10 promoter polymorphism 
was investigated in a black Zimbabwean population. It was observed that IL-10 -
1082 A/G increases the risk to cervical cancer in that population (Stanczuk et al., 
2001). The same group investigated the role of TNF-α promoter polymorphism in 
the same population and showed no association of TNF-α -308 A/G with risk of 
cervical cancer (Stanczuk et al., 2003). The change of amino acid from proline to 
arginine at codon-72 of Tp53 gene was investigated in a black Gambian population. 
No association was found with Tp53 codon-72 polymorphism and risk of cervical 














The studies with South African population are also limited compared to elsewhere 
(Govan et al., 2003;Govan et al., 2006;Govan et al., 2007;Pegoraro et al., 
2000;Pegoraro et al., 2002). Most of the host genetic studies of cervical cancer in 
South Africa were done by our group (Govan et al., 2003;Govan et al., 2006;Govan 
et al., 2007). Tp53 codon-72 polymorphism was investigated in black South African 
and mixed-ancestry population (Govan et al., 2007;Pegoraro et al., 2000;Pegoraro et 
al., 2002). There was no association found with Tp53 codon-72 polymorphism and 
cervical cancer in black (Govan et al., 2007;Pegoraro et al., 2000) and mixed-
ancestry South African populations (Govan et al., 2007). However, Tp53 codon-72 
Arg was found in more cervical cancer patients infected with low or intermediate 
risk HPV in black South African populations (Pegoraro et al., 2002). IFN-γ A/T and 
IL-10 -1082 A/G polymorphisms were found to have no association with cervical 
cancer in black and mixed-ancestry South Africans (Govan et al., 2003). TNF-α -308 
A/G also did not show any association with cervical cancer in black and mixed-
ancestry South African population (Govan et al., 2006). 
 
1.12 Project Motivation 
 
Cervical cancer is the most important cancer in women in developing countries. 
Given that only a fraction of the HPV-infected women develop cervical cancer over 
time, it is very important to understand why some women develop the disease while 
others are able to control the viral infection. HSV-2 infection is a major sexually 
transmitted disease (STD) and is also a co-factor in the development of cervical 













and susceptibility. It is an established fact that host genetics play a role in the 
outcome of infectious diseases and cancer. 
 
Cervical cancer is a multifactorial disease which is dependent on the complex 
interactions of different host and viral factors including environmental factors as 
well. It is evident that individual immune response plays a major role in determining 
the regress or progress of an HPV infection. Host genes are known to play a vital 
role in shaping an individuals immune response to a specific viral infection as well 
as to target malignant cells. This literature review clearly points towards a gap of 
knowledge regarding the host genetic factors that might contribute to persistent HPV 
infection leading to pre-cancer lesions and eventually cancer of the cervix. Some 
contradictory reports on different population have tried to shed light on this field but 
African populations have mostly been untouched till now. 
 
This thesis aims to understand the effects of specific polymorphisms in genes 
involved in cell death pathway (i.e. Fas, FasL and CASP8) and in macrophage 
recruitment (e.g. CCR2) in HSV-2 infection, HPV infection, pre-cancerous cervical 
lesions and cervical cancer in South African women of indigenous black and mixed-
ancestry origin. 
 
As mentioned above in the literature review the prevalence of HPV infection and 
cervical cancer is high in Southern Africa. This is largely due to poor cervical 
screening and treatment programs. Therefore poverty and lifestyle factors are 
regarded as the major reasons for the high incidence of cervical cancer. However, the 













are known to play vital roles in persistent HPV infection and cervical cancer. In this 
thesis we explored the roles of functional polymorphisms of some of the major 
immune response genes and their effects on HPV infection, pre-cancerous lesions, 
cervical cancer and also on HSV-2 infection, a co-factor for developing cervical 
cancer. The understanding of the effects of these polymorphisms leading to 
functional changes on cervical cancer would afford a better understanding of the 
HPV and cervical cancer biology. The implications of our findings not only open up 
the understanding of the host immune response to persistent HPV infection leading 
to cervical cancer and to HSV-2 infection but also help us to understand the 



























FAS AND FASL GENE POLYMORPHISMS ARE NOT 
ASSOCIATED WITH CERVICAL CANCER BUT DIFFER 





The signal generated by the interaction of cell-surface death receptor Fas along with 
FasL triggers apoptosis. Apoptosis is one of the most crucial mechanisms of human 
immune system to eliminate HPV-infected cells. Defects in the cell death pathway 
due to functional polymorphisms in Fas and FasL genes might influence the 
effectiveness of the apoptotic mechanism and hence the outcome of HPV infection 
(the roles of Fas, FasL and their polymorphisms have been reviewed in the literature 
review). FasR-1377G/A, FasR-670A/G and FasL-844T/C polymorphisms have been 
associated with several disorders and also with cervical cancer in different 
populations as described in the literature review. These polymorphisms were not 
studied in African populations with regards to cervical cancer. This chapter focuses 
on the roles of FasR-1377G/A, FasR-670A/G and FasL-844T/C polymorphisms in 

















2.2 Materials and Methods 
 
Participants 
Participants were 447 women with invasive cervical cancer (106 black African and 
341 women of mixed-ancestry) and 424 controls (101 black African and 323 women 
of mixed-ancestry) without cancer of the cervix. Incident cases of symptomatic 
invasive cervical epithelial cancer (stage 1b-IVb), diagnosed a maximum of six 
months previously were recruited from Groote Schuur Hospital and Tygerberg 
Hospital in the Western Cape Province, South Africa. Hospital controls were series 
matched in a ratio of 3:1 to the cases on decade of age, ethnic group and area of 
residence (urban/rural). The control women were selected to be representative of the 
population from which the cases were selected, specifically similar to the cases with 
respect to age, ethnicity and domicile status (urban/rural), so that case-control status 
would not be associated with either of those. The participants of indigenous African 
origin were considered as “black African” and the participants who carried mixed 
lineages in any of their parental ancestry were considered as “mixed-ancestry”. 
There were 264 (59%) urban cases and 183 (41%) rural cases compared to 247 
(58%) urban controls and 177 (42%) rural controls. Participants living in towns or 
cities (according to the national list of towns and cities) were considered as “urbans” 
and participants living in villages or countrysides were considered as “rural”. The 
cases and controls formed part of a study to investigate the association of oral 
















Clinical specimens  
Blood was collected from cases and controls, following written informed consent 
and stored at -80°C. The study was approved by the University of Cape Town 
Research Ethics Committee (REC REF: 075/2009). The subject identifiers were 
permanently unlinked from the specimens. The HIV infection status was known for 
98% (n = 437) of the cases and 94% (n = 398) of the controls and 5% of the cases 
and 4% of the controls were positive for HIV infections. Of the controls 13% were 
positive for high risk HPV by Digene Hybrid Capture II and 14.5% had abnormal 
cervical cytology.   
 
Extraction of genomic DNA 
The genomic DNA was extracted using TotalNucleicAcid Extraction kit for MagNA 
Pure Compact nucleic acid extractor (Roche Diagnostics, Germany). 
 
Determination of FasR/FasL polymorphisms 
Reactions were conducted in 5 μl volumes and contained 10 ng DNA, 1.75 μl PCR 
MasterMix ( Applied Biosystems), 0.087 μl  TaqMan assay mix (FasR-1377 
(rs2234767, assay id, C_12123966_10), FasR-670 (rs1800682, assay id, 
C_9578811_10), FasL844 (rs763110, custom-designed)) (Applied Biosystems) and 
1.16 μl distilled water. Cycling conditions on the ABI prism 7900 HT (Applied 
Biosystems) were 2 minutes at 50˚C, 10 minutes at 95˚C, followed by 40 cycles of 
15 seconds at 92˚C and one minute at 60˚C. End point fluorescence was measured 
immediately after cycling. Alleles were assigned using SDS 2.0 software (Applied 
Biosystems) (Zoodsma et al., 2005) (this work was carried out at Uppsala University, 













(Fig. 2.2) genotype clusters of TaqMan assay measured. The undetermined samples 




Fig. 2.1: One of the genotype clusters for TaqMan assay showing the distribution of 
FasR-670 SNPs. 
Red clusters = Wild type allele (FasR-670A), Blue clusters = Mutant type allele (FasR-670G), Green 















Fig. 2.2: One of the genotype clusters for TaqMan assay showing the distribution of 
FasR-1377 SNPs. 
Red clusters = Wild type allele (FasR-1377G), Blue clusters = Mutant type allele (FasR-1377A), 
Green clusters = Heterozygous (FasR-1377GA) and Black clusters = Undetermined. 
 
The genotyping was cross-checked by sequencing 4 samples for each polymorphism. 














The genotype distributions were tested for deviation from Hardy-Weinberg 
equilibrium (HWE) in controls and also for linkage disequilibrium (LD) in cases and 
controls. HWE is carried out to see whether both allele and genotype frequencies in a 
population remain constant, that is, if they are in equilibrium from generation to 
generation. The main purpose for testing for deviation from HWE is to check for 
possible genotyping errors. Generally HWE is tested only in the controls and not in 
the cases. That is because the controls are randomly selected population which is a 
requirement of HWE. But cases are not random population and a group of 
handpicked individuals with a specific trait. For these analyses, D‟ and r
2 
both were 
used to measure LD for different reasons. The P value described is measured in r
2
 
which is described as correlation coefficient. While the D‟ was used to see the 
distribution of the different loci and their co-relation with each other. Logistic 
regression was used to test for genotype, allelic and haplotype associations with 
cervix cancer status and the linear model was used to test for Genotypes against the 
Baseline characteristics (age, ethnicity and smoking status) and secondary outcomes 
such as HIV status, abnormal cytology (Pap smear) and high risk HPV according to 
Hybrid Capture II HPV Test in the control group. Logistic regression was the 
primary test used for all the analysis. Logistic regression was used since it adjusts for 
confounding factors. Other tests like Chi
2
 do not adjust for confounding factors. We 
created a numerical variable that counted the number of minor alleles for the specific 
polymorphism and tested that in the logistic regression model. All analysis were 
adjusted for ethnicity and smoking. The distribution of different genotypes is known 
to differ among different ethnic groups. Smoking has been pointed in the literature as 













Literature Review section). That led us to adjust for ethnicity and smoking to find the 
true modifiers of the disease. 
 
FasR1377 and FasR-670 both are physically situated in a close proximity which 
might enable these two loci the power to influence each other. That led us to do the 
haplotype analysis with these two loci. We inferred haplotypes from the two 
polymorphisms in FasR, and tested their association with cervix cancer status and 
between ethnicities in the controls. 
 
Statistical analyses were done with R, the freely available environment for graphics 
and statistics (http://www.r-project.org), and R packages dgc-genetics (http://www-
gene.cimr.cam.ac.uk/clayton/software/) and haplo.stats (http://CRAN.R-
project.org/package=haplo.stats). Broadly, haplo.stats uses the expectation 
maximisation (EM) algorithm, to calculate maximum likelihood estimates of 
probabilities, of haplotype pairs (one paternal, one maternal) for each subject, as 
described in Schaid et al. (Schaid et al., 2002) (assisted by the statistics collaborators, 
Dr. Lize van der Merwe and Dr. Ushma Galal (MRC, Cape Town)). 
 
2.3 Results 
The mean age for black cases was 43.8 yrs (SD 9.2) and for mixed-ancestry cases it 
was 45.9 yrs (SD 8.1). The mean age for black controls was 42.9 yrs (SD 9.0) and 
for mixed-ancestry controls it was 45.6 yrs (SD 8.2). No significant differences in 
age or HIV status were observed between cases and controls. The observed genotype 
frequencies of FasR-1377G/A, FasR-670A/G and FasL-844T/C in the controls did 













0.58, FasL-844: P = 0.12). The two FasR polymorphisms were in tight linkage 
disequilibrium (LD) (P < 0.05), except in the black controls (P = 0.078). Neither the 
allelic, nor the genotype frequencies showed a significant association (global P-
values, 0.55, 0.12 and 0.77 for FasR-1377A, FasR-670A and FasL-844T 
respectively) with cervical cancer status (Table 2.1). The global P value is defined as 















Table 2.1  - Counts (n), frequencies (%) and association statistics for genotypes and minor-alleles (FasR-1377G/A, FasR-670A/G, FasL-
844T/C).  
 Black  Mixed-ancestry 
Genotype-cervical cancer 
association, adjusted for 
ethnicity 
 
Genotype-ethnic association, in 
controls only  Cases Controls  Cases Controls  
Genotypes n (%) n (%)  n (%) n (%) P-value OR (95% CI)  P-value OR (95% CI) 
FASR–1377 G→A     0.550   0.004  
GG 74 (77) 75 (83)  186 (64) 196 (66) - 1  - 1 
AG 21 (22) 14 (16)  87 (30) 86 (29) 0.428 1.14 (0.83-1.58)  0.007 0.43 (0.22-0.77) 
AA 1 (1) 1 (1)  17 (6) 13 (4) 0.391 1.37 (0.67-2.87)  0.130 0.20 (0.01-1.04) 
           
A allele  23 (12) 16 (9)  121 (21) 112 (19) 0.275 1.15 (0.89-1.49)  0.003 0.43 (0.24-0.72) 
          
FASR–670 A→G     0.120   0.001  
GG 67 (65) 54 (55)  147 (44) 136 (42) - 1  - 1 
AG 35 (34) 43 (43)  132 (40) 146 (45) 0.099 0.79 (0.59-1.05)  0.207 0.74 (0.46-1.18) 
AA 1 (1) 2 (2)  53 (16) 39 (12) 0.492 1.17 (0.74-1.87)  0.006 0.13 (0.02-0.44) 
           
A allele 37 (18) 47 (24)  238 (36) 224 (35) 0.778 0.97 (0.79-1.19)  0.003 0.57 (0.39-0.82) 
          
FASL –844 T→C     0.770   <0.001  
TT 70 (68) 74 (74)  143 (44) 139 (44) - 1  - 1 
CT 31 (30) 23 (23)  144 (44) 136 (43) 0.515 1.1 (0.82-1.48)  <0.001 0.32 (0.18-0.53) 
CC 2 (2) 3 (3)  40 (12) 40 (13) 0.929 0.98 (0.61-1.57)  0.001 0.14 (0.03-0.41) 
           
C allele 35 (17) 29 (14)  224 (34) 216 (34) 0.797 1.03 (0.83-1.27)  <0.001 0.34 (0.22-0.51) 
                      
P-values and OR (95% confidence intervals) are for test of genotype or additive allelic association with cervix cancer risk, adjusted for ethnicity, and for 
genotype/additive association with ethnicity in controls. For genotypes, P-values next to genotype names are for joint model, others are for ORs of specific 
genotype compared to reference genotype, indicated with OR =1. ORs for alleles are the odds for an additional copy of that allele. ORs for genotype-ethnicity 
association (in controls only) are odds of genotype/allele in black compared to odds of genotype/allele in individuals of mixed-ancestry. Cases = Women with 













The haplotype analysis for FasR-1377/-670 also did not reveal any association with 
cervical cancer in either the black African (global P = 0.1130) (Black) or the mixed-
ancestry (global P = 0.7043) population (Table 2.2). 
 
Table 2.2  - Inferred frequencies, %, for FasR-1377 and FasR 670 haplotypes and odds 
ratios for risk of cervix cancer.  
 Black  Mixed-ancestry 
Haplotype Cases Controls OR (95% CI)  Cases Controls OR (95% CI) 
GG 70 71 1  44 46 1 
GA 18 20 0.8 (0.45-1.43)  36 35 1.08 (0.85-1.38) 
AG 12 5 2.07 (0.87-4.93)  20 19 1.12 (0.83-1.52) 
AA 0 4 -  0 0 - 
                
 
Odds ratios (95% confidence intervals) are for testing FasR-1377 and FasR-670 haplotype association 
with risk of cervix cancer versus reference haplotype GG, stratified by ethnicity. Global P = 0.1130 
(Black) and 0.7043 (Mixed ancestry). 
 
The frequency of -1377A was 12% in black cases and 9% in the black controls, 21% 
in mixed-ancestry cases and 19% in mixed-ancestry controls. -670A was 18% in 
black cases and 24% in black controls, 36% in mixed-ancestry cases and 35% in 
mixed-ancestry controls. -844C was 17% in black cases and 14% in black controls, 
34% in both mixed-ancestry cases and controls (Table 2.1).  
 
The association of three SNPs with ethnicity was investigated only in the control 
group as the controls represent the larger South-African population. In the control 
group, all three SNPs showed significant allelic and genotype differences (global P-
values, 0.004, 0.001, <0.001 for FasR-1377A, FasR-670A and FasL-844T 
respectively) between ethnic groups (Table 2.1). The FasR haplotypes (FasR-1377/-
670) also showed a significant difference (global P-value <0.001) between the two 














Table 2.3  - Inferred frequencies, %, for FasR-1377 and FasR-670 haplotypes and odds 




ancestry OR (95% CI) 
GG 71 46 1 
GA 20 35 0.45 (0.31-0.67) 
AG 5 19 0.33 (0.19-0.58) 
AA 4 0 - 
        
 
Odds ratios (95% confidence intervals) are odds of being black compared to mixed-ancestry, for 
FasR-1377 and FasR 670 haplotypes versus reference haplotype GG, in the control group.  Global P-
value <0.001. 
 
In the control group, both the GA and AG (FasR-1377 and FasR-670) haplotypes 
were more frequent in the mixed-ancestry group relative to black African group 
(AG: 19% compared to 5%; GA: 35% compared to 20%), while the GG haplotype 
was more common in blacks (71%) as compared to the mixed-ancestry group (46%). 
 
No significant association was found between any of the secondary outcomes (HIV 
infection, abnormal cytology (Pap smear) and hybrid capture high risk HPV) and any 





Polymorphisms in the Fas or FasL genes that impair the apoptotic signals have been 
associated with susceptibility to a number of different cancers (Davidson et al., 
1998;Lee et al., 1999;Peters et al., 1999;Sun et al., 2004;Takahashi et al., 













2004;Engelmark et al., 2004;Ivansson et al., 2007a;Lai et al., 2003;Lai et al., 
2005;Sun et al., 2005). We are the first to study the frequency of the FasR-1377G/A, 
FasR-670A/G and FasL844T/C polymorphisms in an indigenous black African as 
well as in a mixed-ancestry population and found no association with cancer of the 
cervix. The tendencies of the odds ratios (ORs) (FasR-1377A/A 1.37, FasR-670A/A 
1.17) point towards an increasing susceptible effect and a need for a larger study. 
Although the result was not statistically significant, there were more cases with 
FasR-1377A variant compared to controls in both black African (12% vs. 9%) and 
mixed-ancestry (21% vs. 19%) women. Our results agree with the lack of association 
of Fas SNPs with cervical cancer shown by three other reports (Dybikowska et al., 
2004;Engelmark et al., 2004;Ivansson et al., 2007a). The differing results between 
studies might be due to one or several factors, including the difference in ethnic 
origin of populations studied and the difference in sample size. The presence of 
another causative mutation in tight LD with any of these three polymorphisms can 
also not be ruled out.  
 
We observed statistically significant allele frequency differences for all the three Fas 
SNPs between ethnic groups in the control women. For FasR-1377G/A, the A allele 
frequency was 9% in the black Africans and 19% in women of mixed-ancestry, 
which were both markedly lower than the frequency in other populations, such as the 
43% and 31% in Taiwanese and Chinese populations, respectively (Lai et al., 
2003;Sun et al., 2005). The FasR-670A allele frequency was 24% in black Africans 
and 35% in women of mixed-ancestry. This is again lower than the average of 53% 
for populations from Europe, Australasia and Asia (Dybikowska et al., 2004;Huang 













FasL-844C alleles was 14% in black women and 34% in women of mixed-ancestry, 
which are very low compared to the 69% and 71% in the Chinese and Swedish 
populations respectively (Ivansson et al., 2007a;Sun et al., 2005). The unusually low 
frequency of the Fas and FasL alleles in the African population could contribute to a 
lower power to detect an association in the present study. 
 
The FasR-1377G/A and FasR-670A/G SNPs are in tight LD in our population. Both 
the AG and GA haplotypes were significantly more frequent in women of mixed-
ancestry compared to GG, the most common haplotype, which was observed at a 




Our study did not show a significant association of the FasR-1377G/A, FasR-
670A/G and FasL-844T/C polymorphisms with cervical cancer. A statistically 
significant difference was found in the allele and genotypes frequencies of the three 
SNPs between women of black African and mixed-ancestry in the control 
population. 
 
HSV-2 is a well known STD and a risk factor cervical cancer. Very little work has 
been done on host genetic susceptibility factors contributing to HSV-2 infection. We 
wanted to find out if the cell death pathway genes, Fas and FasL anyway influence 
















A FAS GENE POLYMORPHISM INFLUENCES HERPES 





Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted virus 
causing genital infections which persist as life-long latent infection in sensory 
neurons. The prevalence of HSV-2 infection is high in the developing world, 
especially in sub-Saharan Africa with higher incidence in women compared to men 
(Ivansson et al., 2007b). Immune surveillance by T cells plays an important role in 
regulating virus infection in human. Activation induced cell death (AICD), regulated 
by the Fas-FasL pathway is a crucial mechanism to eliminate virus-infected cells by 
inducing apoptosis or programmed cell death (Zhang et al., 2004). Therefore, two of 
the best non-HLA genes which are good candidates to investigate if they play a role 
in susceptibility to HSV-2 infection are Fas/CD95 and Fas ligand.  
 
Gene polymorphisms that impact on the apoptotic process will also potentially 
interfere with the processes associated with viral spread and clearance. Fas ligand 
binds to the Fas receptor and activates pro-caspase 8 which forms caspase 8 that 
directs the cells to apoptosis. The signal emanated through transcription factor 
binding sites of stimulatory protein 1 (SP1) and signal transducer and activator of 













of the Fas gene. Three functional polymorphisms in this pathway, namely FasR-
1377G/A, FasR-670A/G and FasL-844T/C have been well studied which might alter 
the cellular apoptosis by dysregulation of Fas-FasL pathway and have also been 
associated with different diseases (Lai et al., 2003;Sibley et al., 2003;Wu et al., 
2003). FasR-670G/G has been associated with protective effect to HIV-related 
lipodystrophy,(Lai et al., 2003) FasR-670A/A conferred a susceptible effect to adult 
T cell leukemia (human T lymphotropic virus type 1-infection) (Lai et al., 2003) and 
cervical carcinogenesis (Lai et al., 2003). FasR-1377A/A has been associated with 
susceptibility to squamous cell carcinoma of the head and neck.(Lai et al., 2003)  
FasL-844T/C has not been associated with any viral infections.  
 
The aim of this study therefore was to investigate role of the three single nucleotide 
polymorphisms from non-HLA genes on individual susceptibility to HSV-2 
infection. 
    
3.2 Herpes Simplex Virus Type-2 
 
HSV-2 belongs to the Alphaherpesviridae group. It is a large, linear, double-stranded 
















Fig. 3.1: A schematic diagram showing the structural conformation of HSV-2 (Novak 
and Peng, 2005). 
 
The genome is packaged into an icosahedral capsid (Shukla and Spear, 2001). This 
capsid is surrounded by a layer of protein called tegument. The tegument is covered 
by a host-cell derived lipid bilayer containing viral different glycoproteins and 
spikes. The glycoproteins are essential for viral infectivity (Akhtar and Shukla, 
2009;Duerst and Morrison, 2003). 
 
3.2.1 Herpes Simplex Virus type-2 infection 
HSV-2 is a common sexually transmitted virus that causes genital infections. HSV-2 
is the major causative agent for genital herpes infection (Bukowski and Welsh, 1986) 
which persists as life-long latent infection in sensory neurons. The virus remains 
latent in neurons after initial infection (Shukla and Spear, 2001). During the latency 
period virus can still spread in infected hosts by asymptomatic shedding of the 
virions to other humans. The virus can be reactivated by a variety of environmental 













reactivation of the virus leads to replication of the virus in epithelial cells and a 
lifetime of intermittent mucocutaneous lesions (Whitley and Roizman, 2001). 
Genital herpes infection is also the primary cause of genital ulcer disease (GUD) 
across the world (World Health Organization, 2001), mainly caused by HSV-2. 
HSV-2 can also cause life-threatening diseases in immunocompromised individuals, 
newborns from infected mothers resulting in fatal encephalitis and in patients with 
HIV (Shukla and Spear, 2001;Whitley and Roizman, 2001). One in 3,500 births in 
the US is affected by HSV-2 infections (Schomogyi et al., 1998). Transmission of 
HSV-2 from one host to another requires sexual intercourse. 
 
Only a handful of countries worldwide have a population-based national estimate of 
HSV-2 to keep track of the spread of HSV-2 infection. A survey in the United States 
indicated an increase in age-adjusted HSV-2 prevalence from 16.4% to 21.7% from 
1976 to 1994 (Fleming et al., 1997). An European cross-sectional survey on age-
standardised HSV-2 seroprevalence conducted between 1989 to 2000 observed a 
range of 4% in England and Wales to 24% in Bulgaria (Pebody et al., 2004). The 
prevalence of HSV-2 infection is much higher in the developing world, especially in 
sub-Saharan Africa with a higher incidence in women compared to men. Age-
adjusted HSV-2 seroprevalence in adults ranges from 30% to 80% in women and 
10% to 50% in men (Weiss, 2004). 
 
Research on the development of a vaccine for protection against HSV-2 infection is 
ongoing (Koelle and Corey, 2008). HSV-2 is known to have different adaptations to 
their human hosts pointing to an evolutionary ancient relationship. This adaptation 













vaccine. It has been pointed that regular use of antivirals such as, acyclovir and 
valacyclovir can reduce HSV-2 shedding by 60-80% and can cut HSV-2 
transmission risk to almost half (Koelle and Corey, 2008). 
 
3.2.2 Herpes Simplex Virus type-2 entry into host cell and its life cycle 
HSV-2 entry into host cells is possibly the most crucial step in viral pathogenesis. 
HSV-2 glycoproteins play an important role in viral entry into host cells. Five viral 
glycoproteins have been identified in viral entry process, namely gB, gC, gD, gH and 
gL (Campadelli-Fiume et al., 2007;Spear, 2004). Other than gC all the glycoproteins 
are essential for viral entry into host cells. Though gC is not essential for viral entry, 
its absence decreases the viral binding to cell-surfaces (Shukla and Spear, 2001). The 
glycoproteins attach to the cell-surface and help the virus to enter into the cell. HSV-
2 entry into host cell and its replication is shown in the following diagram (Fig. 3.2). 
 













The virus enters inside the host cells by two major modes of entry (Akhtar and 
Shukla, 2009). I) HSV-2 virions can enter into cells via a pH-independent fusion of 
viral membrane with the plasma membrane. II) The virus can also enter into the cell 
via an endocytic pathway. For both the pathways HSV-2 particles initially associate 
with filopodia-like membrane protrusions via heparan sulphate proteoglycans 
(HSPGs) (Akhtar and Shukla, 2009). After attachment, the virus penetrates through 
the cell-surface to the cytoplasm. As the virus fuses with a cellular membrane the 
viral nucleocapsid and tegument proteins get released into the host cytoplasm 
(Akhtar and Shukla, 2009). In post-entry steps, HSV-2 nucleocapsids dissociate with 
tegument proteins and bind to dynein motor (Sodeik et al., 1997). Most of the 
tegument proteins participate in activation and modulation of viral gene expression 
and shut-down of host protein synthesis. Some tegument proteins may also 
participate in transport of the nucleocapsids toward the nuclear membrane for 
uncoating and release of viral DNA into the host nucleus (Akhtar and Shukla, 2009). 
Inside the host nucleus, the virus replicates and assemble to form a new virus 
(Akhtar and Shukla, 2009). After replication the virus spreads to another cell and the 
infection grows. 
 
3.3 Immune response to Herpes Simplex Virus type-2 infection 
 
3.3.1 Innate immune response to Herpes Simplex Virus type-2 
Innate immune mechanisms are rapid response to an infection and a relatively 
undiversified reponse. Innate immune responses to virus infection have three phases: 
complement protein and natural-antibody mediated responses, early induced 













cells (DC), neutrophils, macrophages and NK cells (Duerst and Morrison, 2003). 
When an HSV-2 virus attempts to infect the female genital mucosa it first encounters 
mechanical defences that provides a constant barrier to infection. Mucus, Bacterial 
flora and glycocalyx can act as mechanical defense. Genital tract secretions such as 
complement and IgM can also prevent HSV-2 entry into epithelial cells (Duerst and 
Morrison, 2003). If some of the HSV-2 virus breach this defense and replicate in 
epithelial cells, this triggers further activation of complement and stimulates the 
production of chemokines and IFNαβ. These substances alert the DCs and 
macrophages for the presence of HSV-2. The immature DCs carry the HSV-2 
antigens to regional lymph nodes and stimulate T cell activation (Zhou X. et al., 
2003). This helps to alert the systemic adaptive immune response (Duerst and 
Morrison, 2003). After DCs exit the mucosa, cells of the late-induced innate 
response enter. An influx of neutrophils, monocytes and NK cells flood the infected 
region following the gradient of chemokines radiating from the site of infection. 
Once in the infected site, they phagocytose and destroy virus particles and infected 
cells by producing antiviral substances (Duerst and Morrison, 2003). These 
substances also help to activate the adaptive immune response against HSV-2. 
 
3.3.2 Adaptive immune response to Herpes Simplex Virus type-2 
 
Classical adaptive immune responses are mediated by T and B lymphocytes with 
enhanced memory and exclusive antigen specificity. DCs are the most potent APCs 
for stimulating T lymphocytes. The migrations of the DCs to regional lymph nodes 
mature them and help to display viral peptides on MHC molecules. DCs also secrete 













Th1 or Th2 cells. Macrophages and NK cells also produce cytokines that direct Th1 
differentiation, including IL12, IL-18 and IFNγ. T cells especially CD4+ Th1 cells 
and their production of IFNγ are essential for clearing HSV-2 infection (Manickan 
and Rouse, 1995;Milligan et al., 1998). 
 
 
3.4 Herpes Simplex Virus type-2 immune evasions 
 
 
Immune surveillance by T cells plays an important role in regulating virus infection 
in humans. Activation induced cell death (AICD), regulated by the Fas-FasL 
pathway is a crucial mechanism to eliminate virus-infected cells by inducing 
apoptosis or programmed cell death (Zhang et al., 2004). 
 
 
In order for HSV-2 to evade the immune system, it has to overcome the apoptosis of 
the cell which is triggered by the activation of Fas-FasL pathway. HSV evades the 
immune system  in two phases, an early anti-apoptotic phase and a late pro-apoptotic 
















Fig. 3.3: Interaction between HSV and caspase 8 (Novak and Peng, 2005) 
 
In the early anti-apoptotic phase, HSV produces glycoprotein D which activates 
cellular protein NF-κB. NF-κB upon activation enters the nucleus, binds to the DNA 
and reduces the expression of caspase 8 and up-regulates intracellular anti-apoptotic 
molecules which protect the virus-infected cell from Fas-FasL pathway mediated 
apoptosis (Medici et al., 2003). HSV-2 is able to down-regulate the expression of Fas 
L which presents as one mechanism to reduce apoptosis (Sieg et al., 1996). By these 
above processes the virus ensures the survival of the host cell for a sufficient time for 
the virus to replicate. In the second phase, HSV activates Fas-FasL mediated 
apoptosis of immature dendritic cells by down regulation of anti-apoptotic molecules 
and up-regulation of caspase 8. Fas or porforin- mediated cytolysis is essential for 
clearance of HSV-2 from genital epithelium (Dobbs et al., 2005). The elimination of 














3.5 Host genetic risk factors to Herpes Simplex Virus type-2 
infection 
 
There is a report on the association of HLA alleles with HSV-2 infection in a 
Caucasian American cohort. HLA-B27 and -Cw2 showed a protective effect to 
symptomatic HSV-2 infection. On the other hand, HLA-Cw4 showed a susceptible 
effect to HSV-2 infection when compared with non-infected individuals (Lekstrom-
Himes et al., 1999). To the best of our knowledge, no previous studies have 
investigated the roles of Fas/FasL polymorphisms in susceptibility to HSV-2 
infection. 
 
3.6 Materials and Methods 
 
Study Participants 
Participants were 424 controls (101 black African and 323 women of mixed-
ancestry) without cancer of the cervix. All participants were unrelated subjects. The 
study was approved by the University of Cape Town Research Ethics Committee 
(REC REF: 075/2009). This is a secondary analysis focusing on risk of HSV-2 




The HSV-2 status of 407 of these 424 women was assessed. HSV-2 was detected by 













Diagnostics, Inc., CA, USA) screening of the sera aliquots according to 
manufacturer‟s instructions. Antibodies to HSV-2 are markers of infection.  There 
was no information available on which women were asymptomic or alternatively 
shedding HSV-2. This test has been validated by other researchers as a method of 
testing for HSV-2 antibodies in Africans (Shapiro et al., 2003). The index cutoff 
value for our test was 0.90 which was calculated as an average of four optical density 
(OD) calibrators and was in line with the company manuals supplied with the kit. 
There were 84.2% high positives (3.5 OD or greater) and 15.3% were low positives 
(below 3.5 OD, but greater than 1.1 OD). Values between 0.9 OD and 1.1 OD were 
considered as indeterminate. There were very few indeterminate values (0.5%) 
which will not affect the outcome of our results (this work was carried out by the 
NHLS Medical Virology Division, Groote Schuur Hospital, Cape Town, Republic of 
South Africa). 
 
Extraction of Genomic DNA and Genotyping 
Reactions were conducted in 5 μl volumes and contained 10 ng DNA, 1.75 μl PCR 
MasterMix (Applied Biosystems), 0.087 μl  TaqMan assay mix (FasR-1377 
(rs2234767, assay id, C_12123966_10), FasR-670 (rs1800682, assay id, 
C_9578811_10), FasL844 (rs763110, custom-designed)) (Applied Biosystems) and 
1.16 μl distilled water. Cycling conditions on the ABI prism 7900 HT (Applied 
Biosystems) were 2 minutes at 50˚C, 10 minutes at 95˚C, followed by 40 cycles of 
15 seconds at 92˚C and one minute at 60˚C. End point fluorescence was measured 
immediately after cycling. Alleles were assigned using SDS 2.0 software (Applied 

















The genotype distributions were tested for deviation from Hardy-Weinberg 
equilibrium (HWE) and also for linkage disequilibrium (LD). HWE is carried out to 
see whether both allele and genotype frequencies in a population remain constant, 
that is, if they are in equilibrium from generation to generation. Logistic regression 
was used to test for genotype, allelic and haplotype associations with HSV-2 
positivity status as well as baseline characteristics (age, ethnicity and smoking status) 
and secondary outcomes such as HIV status, abnormal cytology (Pap smear) and 
high risk HPV according to Hybrid Capture II HPV Test. We created a numerical 
variable that counted the number of minor alleles for the specific polymorphism and 
tested that in the logistic regression model. 
 
We inferred haplotypes from the two polymorphisms in FasR, and tested their 
association with HSV-2 infection status and between ethnicities in the group under 
investigation. 
 
Statistical analyses were done with R, the freely available environment for graphics 
and statistics (http://www.r-project.org), and R packages dgc-genetics (http://www-
gene.cimr.cam.ac.uk/clayton/software/) and haplo.stats (http://CRAN.R-
project.org/package=haplo.stats). Broadly, haplo.stats uses the expectation 













probabilities, of haplotype pairs (one paternal, one maternal) for each subject, as 
described in Schaid et al. (Schaid et al., 2002). 
 
Logistic regression enabled us to adjust all tests for the known confounder, ethnicity 
(genotype and allele frequencies differed significantly between the ethnic groups), by 
including it as a covariate in each model. We did not adjust our results for multiple 
testing. We felt that a Bonferroni adjustment, multiplying all p-values with 3, would 
be very conservative when taking into account that the SNPs were in tight LD 
(results not shown) (assisted by the statistics collaborators, Dr. Lize van der Merwe 




The mean age for the HSV-2 infected Black women was 42.8 (SD 8.8) and for the 
HSV-2 infected women of mixed-ancestry it was 46.6 (SD 7.6). The mean age for 
the HSV-2 non-infected Black women was 42.8 (SD 11.1) and for the HSV-2 non-
infected women of mixed-ancestry it was 43.9 (SD 8.8). The mean age among the 
women whether HSV-2 infected and non-infected were not significantly different. 
Among black women, 89% were positive for HSV-2 infection and among mixed-
ancestry women 58% were positive for HSV-2 infection. A statistically significant 
association (p-value = 0.029) was found between the FasR-1377G/A SNP and HSV-
2 infection, after adjusting for ethnicity. The FasR-1377A allele were associated with 
a highly significant decreased risk (p-value = 0.008, OR = 0.58 (95% CI: 0.38-0.87)) 
of HSV-2 infection, after adjusting for ethnicity, with a frequency of 41.5% in HSV-













Table 3.1: Counts (n) and percentage (%) distributions for genotypes (FasR-1377G/A, 
FasR-670A/G, FasL-844T/C), and minor alleles. P-values and odds ratios for 
association with HSV-2 status, adjusted for ethnicity. 
 
 Black Mixed-ancestry SNP-HSV-2 association, 










n 88 11 177 131     
  n (%) n (%) n (%) n (%) P-value OR (95% CI) 





GG 70 (85) 5 (71) 117 (73) 73 (60)  1 
AG 12 (15) 1 (14) 38 (24) 42 (34) 0.033 0.57 (0.35-0.96) 
AA 0 (0) 1 (14) 5 (3) 7 (6) 0.069 0.33 (0.09-1.06) 
       
A allele  12 (7) 3 (21) 48 (15) 56 (23) 0.008 0.58 (0.38-0.87) 
       
FASR–670 A→G    0.486  
GG 46 (53) 7 (64) 76 (43) 56 (43)  1 
AG 38 (44) 4 (36) 82 (47) 55 (42) 0.576 1.14 (0.72-1.8) 
AA 2 (2) 0 (0) 18 (10) 19 (15) 0.406 0.74 (0.36-1.52) 
       
A allele 42 (24) 4 (18) 118 (34) 93 (36) 0.724 0.94 (0.68-1.3) 
       
FASL–844 T→C    0.829  
TT 2 (2) 0 (0) 21 (12) 18 (14)  1 
CT 22 (25) 1 (9) 74 (43) 54 (42) 0.612 1.13 (0.71-1.81) 
CC 63 (72) 10 (91) 76 (44) 57 (44) 0.869 0.94 (0.47-1.92) 
       
C allele 26 (15) 1 (5) 116 (34) 90 (35) 0.920 1.02 (0.74-1.40) 
 
P-values and odds ratios are for test of genotype/additive association with herpes risk, adjusted for 
ethnicity. P-values next to SNP names are for joint model; others are for odds ratios of specific 
genotype compared to reference genotype (indicated with OR=1). ORs for alleles are the odds for 
each additional copy of that allele. 
 
The significance of this result remains even after a Bonferroni adjustment of 
multiplication with 3. No statistically significant association was found between 
FasR-670A/G or FasL-844T/C polymorphisms and risk of HSV-2. A highly 
significant association (Global p-value = 0.0001) was found between HSV-2 and the 














Table 3.2: Inferred frequencies (%), and association statistics for testing FasR-1377 
and FasR-670 haplotype association with risk of HSV-2, stratified by ethnicity. Global 




                   
HSV-2 
non-
infected  OR (95% CI) 
GG 57 43 1 
GA 31 34 0.66 (0.47-0.93) 
AG 12 23 0.42 (0.28-0.64) 
AA - - - 
 
Specifically, the FasR-1377/-670 AG haplotype showed a decreased risk (OR = 0.42 
(95% CI: 0.28-0.64)) of HSV-2 infection with a frequency of 12% in HSV-2 infected 
women and 23% in HSV-2 non-infected women compared to the GG haplotype, with 
a frequency of 57% for HSV-2 infected compared to 43% for HSV-2 non-infected 
women (Table 3.2). The FasR-1377/-670 GA haplotype also showed a decreased risk 
(OR = 0.66 (95% CI: 0.47-0.93)) of HSV-2 infection with a frequency of 31% in 
HSV-2 infected women and 34% in HSV-2 non-infected women compared to the 




We assessed the association between HSV-2 status and genotype, allelic (additive) 
and haplotype respectively, for three SNPs in a study group consisting of two ethnic 
groups. We did not test the ethnic groups separately, because we know, from the 













distributions are not the same for the ethnic groups. Therefore, we adjusted for 
ethnicity by including it as a covariate in the logistic regression models. 
 
Our analysis showed that FasR-1377A allele was associated with reduced risk of 
infection with HSV-2, after adjusting for ethnic origin. The association was further 
confirmed in the FasR-1377A/G genotype. The observation of an association of the 
AG haplotype of FasR-1377/-670 with reduced HSV-2 infection could mainly be due 
to the FasR-1377A allele since the FasR-670A/G polymorphism did not show 
significant difference between infected and uninfected when analyzed separately.  
 
The life cycle of HSV is extremely complex. The first step is viral entry where 
multiple HSV and cellular proteins play a role (Heldwein and Krummenacher, 2008). 
At different times of the HSV-2 life cycle apoptosis is promoted to allow virus to 
spread to other cells or apoptosis is prevented during periods of latency. Therefore, 
HSV is able to affect the apoptotic pathways in many ways and these are also 
dependent on the phase of the life cycle and which cells are infected (Carter, 2008). 
However, these apoptotic events are associated with events post HSV infection and 
not with events that could be associated with preventing HSV infection. Our study 
has shown a possible link with FasR-1377A allele and the reduction of HSV-2 
infection. This allele is associated with decreased Fas expression which would imply 



















In conclusion, our study reports on a possible role for FasR-1377A/G SNP in HSV-2 
infection which is a novel result. This information adds on the growing literature on 
the host genetic susceptibility factors to HSV infection. However, the main limitation 
of this study is that it was done as a secondary analysis. The results should be 
interpreted cautiously as the subjects in this study were not selected primarily for the 
study of HSV-2 infection; however, these findings open the possibility of new 
studies focusing on other non-HLA genetic factors in HSV-2 infection. Further 
studies on well defined and large cohorts are needed to further confirm our findings 































CASP8 PROMOTER POLYMORPHISM IS ASSOCIATED WITH 
HIGH-RISK HPV TYPES AND ABNORMAL CYTOLOGY BUT 





Cervical cancer is a multistep process that develops slowly over several years due to 
persistent infection of the epithelial cells with human papillomavirus (HPV). HPV 
infection may lead to atypical squamous cells of undetermined significance 
(ASCUS) or squamous intraepithelial lesions (SIL) (Rohan et al., 2003). 90% of 
ASCUS regresses to normal cytology. Approximately 30.8% of the ASCUS positive 
individuals are HPV-infected according to Digene Hybrid Capture II test (Allan et 
al., 2006) while the rest could be due to other stresses by different environmental 
factors. Approximately 63.2% of the LSIL and 83% of the HSIL positive individuals 
are HPV-infected according to Digene Hybrid Capture II test (Allan et al., 2006). 
LSILs are precancerous and are very early precursor stages of cervical cancer with 
very few cases progressing to cancer (Snijders et al., 2006). On the other hand, most 
HSILs progress to invasive cervical cancer (ICC) if not treated on time. 
 
The human immune system eliminates HPV-infected cells and the pre-cancerous 
malignant cells by apoptosis (Garnett and Duerksen-Hughes, 2006). The spread of 













system. Any defect in this pathway leads to inefficiency of the apoptotic mechanism 
which helps in cancer progression (Cotter, 2009). Caspase-8 is one of the most 
important proteins in this pathway that generates apoptotic signals. Functional 
polymorphism at the CASP8 gene that encodes Caspase-8 might lead to altered 
apoptotic signals affecting the spread of the pre-cancerous lesions. CASP8 -652 6N 
ins/del polymorphism has been studied in different populations as described in the 
literature review. But no investigation has been done with this polymorphism in 
African population. This polymorphism has also been shown to influence the 
susceptibility to cervical cancer in one of the studies (Sun et al., 2007). This variant 
has a direct functional effect on risk of tumour progression as it decreases CASP8 
transcription and hence reduction in caspase-8 expression (Sun et al., 2007). 
Biochemical analyses have also shown that T lymphocytes with the deletion variant 
display reduced caspase-8 activity and reduced AICD when stimulated with cancer 
cell antigens (Sun et al., 2007). 
 
4.2 Materials and Methods 
 
Participants 
DNA from a total of 1854 subjects comprising 447 women with invasive cervical 
cancer (106 black African and 341 women of mixed-ancestry) and 1407 controls 
(314 black African and 1093 women of mixed-ancestry) without cancer of the cervix 
was studied. There were 264 (59%) urban cases and 183 (41%) rural cases compared 
to 715 (53%) urban controls and 632 (47%) rural controls (residency status was not 














The mean age for black cases was 43.8 yrs (SD 9.2) and for mixed-ancestry cases it 
was 45.9 yrs (SD 8.1). The mean age for black controls was 42.3 yrs (SD 9.1) and 
for mixed-ancestry controls was 44.3 yrs (SD 8.4). The HIV infection was 5% for the 
cases and 4.7% for the controls. No significant differences in age or HIV status were 
observed between cases and controls (data not shown here). Among 1230 controls 
for which pap smear results were available, 180 (15%) were abnormal (87 (7%) with 
SIL (LSIL and HSIL), 43 (3%) with HSIL and 93 (8%) ASCUS) and 1050 (85%) 
were normal. Smoking activity differed significantly between the cases and the 
controls (P = 0.001, OR (95% CI) = 1.60 (1.23-2.07), adjusted for ethnicity) (data 




Papanicolaou test (Pap smear) was conducted on endocervical scrapings taken from 
the control women to test for cervical cytology as previously described (Shapiro et 
al., 2003). For this study, samples displaying ASCUS (atypical squamous cells of 
undetermined significance), LSIL or HSIL were considered as abnormal cytology. 
 
High-risk HPV type detection 
Endocervical scrapings from control women were assayed for HPV infection using 
the Hybrid Capture II HPV Test for the detection of high risk HPV types 
16/18/31/33/35/39/45/51/52/56/58/59/68, and classified positive according to the 
manufacturer‟s instructions (Digene Corporation, Gaithersburg, MD, USA) as 













Hybrid Capture test was done were positive and 85% (1050) were negative. Each 
female was represented by a single cytological specimen. 
 
Extraction of genomic DNA 
The genomic DNA was extracted using TotalNucleicAcid Extraction kit for MagNA 
Pure Compact nucleic acid extractor (Roche Diagnostics, Germany).  
 
Determination of CASP8 -652 6N ins/del polymorphism 
The CASP8 -652 6N ins/del polymorphism (rs3834129:–/AGTAAG; NM_001228.4) 
was determined using a polymerase chain reaction (PCR) – restriction fragment 
length polymorphism (RFLP) method followed by agarose gel electrophoresis as 
described by Sun T et. al. (Sun et al., 2007). PCR reactions were carried out for each 
sample using a forward primer and a reverse primer. 130ng of genomic DNA was 
amplified in a 10-μl reaction mixture containing 10picomoles of each CASP8 -652 
6N ins/del primers: F, 5‟CTGCATGCCAGGAGCTAAGT3‟ and R, 
5‟GCCATAGTAATTCTTGCTCTGC3‟ (Sun et al., 2007) and 5-μl 2x ImmoMix
TM
 
(Bioline). PCR cycle reactions were performed on an ABI 2720 Thermal Cycler 
(Applied Biosystems, Foster City, CA) beginning with a denaturing step at 94⁰C for 
2 min followed by 30 cycles of denaturing at 94⁰C for 20 s, annealing at 53⁰C for 10 
s and extension at 72⁰C for 15 s followed by a final extension at 72⁰C for 5 min. The 
cases and controls were generally not mixed in plates except for a few occasions. At 
times when cases and controls were mixed on plates, the statuses of the samples were 
unknown and the genotype calling was blind to case-control status. A DNA free 
negative sample, known positive sample for wild type homozygous and known 













had a positive control sample included and it was always picked up as positive 
giving us assurance of the obtained genotypes were the correct ones. 
 
The primers generated PCR products of either 177bps (CASP8 -652 6N ins) or 
171bps (CASP8 -652 6N del). The amplified PCR products were digested by the BfaI 
restriction enzyme (New England Biolabs, MA, USA) using New England Buffer 4 
(10x) for overnight. 
 
The digested PCR products were analysed on 1.5% agarose gel stained with ethidium 
bromide using a 25bp DNA Step Ladder (Promega Corporation, Madison, USA). 
The samples with CASP8 -652 6N ins variant produced two fragments of 31 base 
pairs (bps) and 146bps. The samples with CASP8 -652 6N del allele produced one 
fragment of 171bps. Heterozygous samples (CASP8 -652 6N ins/del) produced all 
the three fragments of 31bps, 146bps and 171bps. The fragment of 31bps was not 





Figure 4.1  - Analysis of the CASP8 -652 6N ins/del polymorphism on agarose gel. 
 
M = DNA ladder, samples 1 and 3 = CASP8 -652 6N ins/ins (wild type homozygous), samples 5 and 
6 = CASP8 -652 6N ins/del (heterozygous), sample 7 = CASP8 -652 6N del/del (mutant type 















DNA sequencing was carried out in a random manner for 40 samples to cross-check 
the genotyping results. The same forward primer (previously used for genotyping of 
CASP8 -652 6N ins/del) and a new reverse primer 
(5‟CCTCTTCAATGCTTCCTTGAG3‟) was used for sequencing both DNA strands 
(forward and reverse). The DNA sequencing was done using a BigDye Teminator 
V3.1 Cycle sequencing kit (Applied Biosystems, Foster City, CA) following the 
manufacturers protocol. The reproducibility of the sequencing results were 100% to 
the previous genotyping results. 
 
Statistical Analysis 
The genotype distributions were tested for Hardy-Weinberg equilibrium in cases and 
controls. Logistic regression was used to test for genotype associations with cervix 
cancer status as well as baseline characteristics (age, ethnicity and smoking status) 
and secondary outcomes such as HIV status and abnormal cytology (Pap smear) in 
the control group. Statistical analyses were done using Stata 9 software (Texas, 
USA). 
4.3 Results  
 
The observed genotype frequencies for CASP8 -652 6N ins/del polymorphism did 
not deviate from HWE for the black controls (P = 0.614) (data not shown here) but 
deviated slightly in the mixed-ancestry controls (P = 0.045) (data not shown here). 
Genotyping data for CASP8 -652 6N ins/del polymorphism was obtained on 445 of 
the 447 cases and 1221 of the 1407 controls. The frequency of CASP8 -652 6N del 
allele was 53% in black cases and 58% in the black controls and 47% in mixed-













CASP8 -652 6N ins/del polymorphism did not show statistically significant 
association (P = 0.948) with cervical cancer (Table 4.1).  
 
Table 4.1  - Association statistics for CASP8 -652 6N ins/del genotypes for cases and 
controls. 
 













association, adjusted for 
ethnicity and smoking 
Genotypes n (%) n (%) n (%) n (%) P-value OR (95% CI) 
CASP8 -652 6N ins→6N del      
ins/ins 43 (17) 265 (26) 18 (17) 84 (25) - 1 
ins/del 129 (50) 510 (53) 63 (59) 188 (55) 0.247 0.85 (0.65-1.12) 
del/del 85 (33) 189 (21) 25 (24) 67 (20) 0.948 1.01 (0.73-1.41) 
 
P-values and OR (95% confidence intervals) are for test of genotype association with cervix cancer 
risk, adjusted for ethnicity and smoking. Cases = Women with cancer of the cervix (ICC), Controls = 
Women without cancer of the cervix, n = counts. 
 
Stratifying into ethnic groups also did not show any significant association of this 
polymorphism with either black African (P = 0.313, data not shown here) or with 
women of mixed-ancestry (P = 0.591, data not shown here). 
 
The association of this (CASP8 -652 6N ins/del) polymorphism was then 
investigated in the control group with abnormal cytology and high-risk HPV 
infection. When individuals with abnormal cytology (positive for ASCUS, LSIL or 
HSIL) were compared to individuals with normal cytology, a statistically significant 
association (P = 0.048) was found with CASP8 -652 6N del/del genotype and 


















Table 4.2  - Association statistics for CASP8 -652 6N ins/del genotypes according to 
cytology in the control group. 
 























CASP8 -652 6N ins→6N del      
ins/ins 32 (18) 227 (29) 7 (13) 23 (22) - 1 
ins/del 95 (54) 408 (51) 23 (41) 62 (59) 
0.165 1.37 (0.88-
2.14) 





Abnormal cytology = Positive for pap smear test (i.e. positive for ASCUS + positive for LSIL + 
positive for HSIL), Normal cytology = Negative for pap smear test. 
 
 
Comparing the high-risk HPV-infected individuals with non-HPV-infected 
individuals showed a borderline association (P = 0.058) with CASP8 -652 6N del/del 




















Table 4.3  - Association statistics for CASP8 -652 6N ins/del genotypes for high-risk 




negative (n = 
933) 
High-risk HPV 







































CASP8 -652 6N 
ins→6N del    
    
ins/ins 32 (19) 213 (28) 7 (12) 37 (27) - 1   
ins/del 94 (54) 400 (53) 
24 





del/del 47 (27) 147 (19) 
29 






High-risk HPV negative = Negative for Hybrid Capture II HPV Test, High-risk HPV positive = 
Positive for Hybrid Capture II HPV Test. 
 
When the high-risk HPV infection data was separately analysed in both the black 
African and women of mixed-ancestry, a statistically significant association (P = 
0.030) was found with high-risk HPV infection and CASP8 -652 6N del/del 
genotype in black Africans (Table 4.3), but not in women of mixed-ancestry (P = 
0.551, data not shown here). 
 
CASP8 -652 6N ins/del polymorphism was not found in LD with FasR-1377G/A (D‟ 
= 0.129, LOD = 0.47, r
2
 = 0.004), FasR-670A/G (D‟ = 0.076, LOD = 0.29, r
2
 = 
0.002) and FasL-844T/C (D‟ = 0.042, LOD = 0.09, r
2













1377G/A and FasR-670A/G were in tight LD (D‟ = 1.0, LOD = 20.87, r
2
 = 0.101) 




Fig. 4.2: An LD plot showing the r
2
 value for the three genes studied in this project. 
 
Marker 1 = FasR-1377G/A, Marker 2 = FasR-670A/G, Marker 3 = FasL-844T/C, Marker 4 = CASP8 
-652 6N ins/del. The numbers in the box represent r
2
 as a percentage. 
 
The haplotype analysis of CASP8 -652 6N ins/del with all the three Fas/FasL 
polymorphisms did not show any association with cervical cancer. 
 
4.4 Discussion  
 
Not much is known about the genetic variations in the CASP8 gene and their roles in 
human cancer susceptibility. CASP8 -652 6N ins/del polymorphism has been 
associated with several pathological conditions including different  types of cancers 
in different populations with conflicting results (Cybulski et al., 2008;De et al., 
2009;Frank et al., 2008;Ji et al., 2009;Li et al., 2008;Ni et al., 2009;Pittman et al., 
2008;Sun et al., 2007;Wang et al., 2009;Yang et al., 2008). This polymorphism has 
also been shown to influence the susceptibility to cervical cancer in one of the 













progression as it decreases CASP8 transcription and hence reduction in caspase-8 
expression (Sun et al., 2007). Biochemical analyses have also shown that T 
lymphocytes with the deletion variant display reduced caspase-8 activity and reduced 
AICD when stimulated with cancer cell antigens (Sun et al., 2007). 
 
We are the first to study the frequency of the CASP8 -652 6N ins/del polymorphism 
in an indigenous black African as well as in a population of mixed-ancestry. We did 
not find a significant association of CASP8 -652 6N del/del genotype and cervical 
cancer (P = 0.948) when comparing control women of black African and mixed-
ancestry origin. The frequency of the CASP8 -652 6N del/del allele was found to be 
26% in Chinese population whereas it was 58% for black African and 46% for 
mixed-ancestry in our population. It has been previously reported that a mutated 
form of caspase-8 acts in a dominant-negative manner preventing the recruitment of 
the wild type forms of caspase-8 to death receptors (Kim et al., 2003;Mandruzzato et 
al., 1997). This results in a blockage of signal transduction via the death receptor and 
apoptotic cell death pathway (Kim et al., 2003;Mandruzzato et al., 1997). This is 
supported by our observation of an increased likelihood of having abnormal cytology 
(ASCUS + LSIL + HSIL) (P = 0.048) among carriers of the CASP8 -652 6N del/del 
genotype compared to individuals with normal cytology. High-risk HPV infection 
also showed a borderline significant effect (P = 0.058) with CASP8 -652 6N del/del 
genotype. However, on separating the two ethnic groups, the black subjects 
presented with significantly higher risk of HPV infection (P = 0.030) if they were 
carriers of the CASP8 -652 6N del/del genotype. As the association of this genotype 
is not observed with the cervical cancer patients which suggests that majority of the 













cancerous lesions regress. This would imply that those with the CASP8 -652 6N 
del/del genotype do not progress to cancer of the cervix with a mechanism hitherto 
unknown. We hypothesize that the shift in roles of CASP8 -652 6N del/del genotype 
happens somewhere during the early stages pre- cancer development including HPV 
infection. 
 
It has been reported that several isoforms of caspase-8 exist, most common of them 
all is caspase-8 long (caspase-8L) which results from a 136 bp deletion (Mohr et al., 
2005). It lacks proteolytic activity and does not facilitate signal transduction from 
activated death receptors acting in a dominant-negative manner (Fulda, 2009). Thus, 
caspase-8L distribution in different populations may affect the observed effects of 
the CASP8 -652 6N ins/del polymorphism. Its distribution in the current study 
population is not known. More studies are needed to really tease out what could be 
the contributory factor in the observed ethnic differences as well as non-association 
of the CASP8 -652 6N with cervical cancer, an observation reported by our group. It 
is important to note that CASP8 -652 6N deletions, is not the only way caspase-8 
expression is lost. A recent report shows that DNA methylation of CASP8 gene is 
also used to switch off caspase-8 expression (Wu Y et al., 2010). Thus, we might not 
have found a difference in the distribution of the CASP8 -652 6N ins/del between 
cases and controls but the actual expression levels might be significantly different. 
Though there is evidence that genetic frequency difference in different races do not 
generally influence their biological impact on a disease (Ioannidis et al., 2004), the 
possibility still remains. The presence of another causative mutation in tight LD with 














 However, it has been shown that the death receptor pathway behaves aberrantly in 
early stages of precarcinogenic lesions, dysplasia and carcinoma in situ (Gratas et al., 
1998;Kase et al., 2002). We hypothesize that during early stages of cancer 
development the caspase-cascade, mediated mainly by the death receptor pathway 
activates apoptosis in malignant cells. This will eliminate the malignant cells and 
slow down the process of cancer development. Individuals carrying the CASP8 -652 
6N del/del variant will express less caspase-8 hence less apoptosis of the malignant 
cells leading to a faster progression of tumour compared to the individuals carrying 
the CASP8 -652 6N ins/ins variant of it. Our results showing a significant susceptible 
effect with abnormal cytology (Table 4.2) and with high-risk HPV infection (Table 
4.3) with the deletion variant of CASP8 (CASP8 -652 6N del/del) support this 






Figure 4.3 - Schematic diagram showing the role of CASP8 -652 6N del/del variant 






























Our study did not show any significant association of CASP8 -652 6N ins/del 
polymorphism with cervical cancer, but showed a statistically significant association 
with abnormal cytology in black African women and women of mixed-ancestry. We 
also showed a significant effect of this polymorphism with high-risk HPV infection 
in black African women. CASP8 -652 6N del/del genotype increased the risk of 
developing abnormal cytology in black African women and women mixed-ancestry 
and increased the risk of high-risk HPV infection in black African individuals. 
Further studies are needed with patients at different stages of cervical cancer to 



























CCR2-V64I POLYMORPHISM IS ASSOCIATED WITH 
INCREASED RISK OF CERVICAL CANCER BUT NOT WITH 




The human immune system releases chemokines that triggers recruitment of local 
inflammatory and immune cells as one of the earliest responses to HPV infection. 
CCR2 is one of the major chemokines and a receptor for the MCP-1, produced 
largely by tumour cells. MCP-1 is responsible for recruiting macrophages to cervical 
tumours. Macrophages have multifactorial role in tumour progression, with tumour-
cytotoxic characteristics in early stages and a supporting role in tumour angiogenesis 
during late stages. Functional polymorphism at CCR2 gene might influence the 
recruitment of macrophages to tumours and affect the outcome of the tumour 
progression. CCR2V64I polymorphism has been well studied in different diseases 
including cervical cancer as described in the literature review but not within an 
African population. This chapter focuses on the role of CCR2V64I in cervical cancer 


















5.2 Materials and Methods 
 
Participants 
A total of 1878 subjects comprising 446 women with invasive cervical cancer (106 
black African and 340 women of mixed-ancestry) and 1432 controls (322 black 
African and 1110 women of mixed-ancestry) without cancer of the cervix were 
recruited. There were 264 (59%) urban cases and 182 (41%) rural cases compared to 
718 (53%) urban controls and 632 (47%) rural controls (residency status was not 
known for 82 controls). 
 
The mean age for black cases was 43.8 yrs (SD 9.2) and for cases of mixed-ancestry 
it was 46.0 yrs (SD 8.1). The mean age for black controls was 42.3 yrs (SD 9.0) and 
for controls of mixed-ancestry it was 44.3 yrs (SD 8.4). The HIV infection status was 
4.8% for the cases and 4.7% for the controls. No significant differences in age or 
HIV status were observed between cases and controls (data not shown here). Among 
1258 controls for which pap smear results were available, 185 (15%) were abnormal 
(91 (7%) had SIL (LSIL and HSIL) and of these 45 (4%) had HSIL) and 1070 (85%) 
were normal. A significant difference in the degree of smoking was found between 
the cases and the controls (P = 0.004) (data not shown here). Subsequently, all the 
analyses were adjusted for the smoking status along with ethnicity.  
 
Papanicolaou test 
Endocervical scrapings were taken from the control women to conduct papanicolaou 
tests (Pap smears) to check for cervical cytology as previously described (Shapiro et 
al., 2003). For this study, all ASCUS (atypical squamous cells of undetermined 














Extraction of genomic DNA 
The genomic DNA was extracted using TotalNucleicAcid Extraction kit for MagNA 
Pure Compact nucleic acid extractor (Roche Diagnostics, Germany).  
 
Determination of CCR2-V64I polymorphism 
The CCR2-V64I (rs 3918354) polymorphism was determined by polymerase chain 
reaction (PCR) using sequence-specific primers (SSP) followed by agarose gel 
electrophoresis. Two PCR reactions were carried out for each sample using two 
different forward primers (CCR2-64V and CCR2-64I) and a reverse primer. 130ng 
of genomic DNA was amplified in a 10-μl reaction mixture containing 10picomoles 
of each CCR2-V64I primers: F(CCR2-64V), 5‟TGGGCAACATGCTGGTCG3‟ or 
F(CCR2-64I), 5‟TGGGCAACATGCTGGTCA3‟ and R, 
5‟TGGAAAATAAGGGCCACAGAC3‟ (Tang et al., 1999) and 5-μl 2x 
ImmoMix
TM
 (Bioline). PCR cycle reactions were performed on an ABI 2720 
Thermal Cycler (Applied Biosystems, Foster City, CA) beginning with a denaturing 
step at 95⁰C for 2.5 min followed by 10 higher-stringency cycles of denaturing at 
94⁰C for 25 s, annealing at 60⁰C for 45 s and extension at 72⁰C for 45 s again 
followed by 21 lower-stringency cycles of denaturing at 94⁰C for 25 s, annealing at 
58⁰C for 40 s and extension at 72⁰C for 40 s with a final extension at 72⁰C for 6 min. 
The PCR reaction conditions were adapted and modified from Tang J et. al. (Tang et 
al., 1999). 
 
The amplified PCR products of 413 base pairs (bp) were analysed by running on 















DNA Ladder, ready-to-use (Fermentas Inc, Ontario, Canada). The samples with a 
wild type allele (G) at position 190 of the CCR2 gene amplified the PCR containing 
CCR2-64V forward primer and showed no products for the PCR containing CCR2-
64I forward primer. Likewise, samples with a mutant allele (A) at position 190 of the 
CCR2 gene did not show any product for the PCR containing CCR2-64V forward 
primer rather amplified the PCR containing CCR2-64I forward primer. The 
heterozygous samples showed products for both the PCR containing CCR2-64V as 
well as CCR2-64I forward primers (Fig. 5.1). 
 
 
Figure 5.1  - Analysis of the CCR2-V64I genotypes on agarose gel. 
L = DNA ladder, samples 1 and 2 = GG (CCR2-64V – wild type homozygous), samples 3 and 4 = GA 
(CCR2-V64I – heterozygous), samples 5 and 6 = AA (CCR2-64I – mutant type homozygous), W = 
PCR amplifying wild type variant (CCR2-64V), M = PCR amplifying mutant type variant (CCR2-
64I). 
 
The genotyping was cross-checked by DNA sequencing of 40 samples, 10 each for 
wild type, mutant type, heterozygous and 10 randomly selected samples using a 
forward primer (5‟TACGGTGCTCCCTGTCATAAA3‟) and the same reverse 
primer previously used for genotyping of CCR2. The DNA sequencing was done 
using a BigDye Teminator V3.1 Cycle sequencing kit (Applied Biosystems, Foster 
City, CA) following the manufacturers protocol. Other than the mutant type samples, 
all the other samples showed 100% confirmation of our genotype results. Due to 













sequence all the mutant samples. Among all the 125 mutant samples (as assigned 
according to PCR amplification and agarose gel results) only 3 did not show any 
result in both forward and reverse primer sequencing and were excluded from the 
final analysis. The rest of the 122 samples showed clear sequencing results of either 
GG, AG or AA and were scored accordingly. 
 
Statistical Analysis 
The genotype distributions were tested for Hardy-Weinberg equilibrium in cases and 
controls. Logistic regression was used to test for genotype associations with cervix 
cancer status as well as baseline characteristics (age, ethnicity and smoking status) 
and secondary outcomes such as HIV status and abnormal cytology (Pap smear) in 
the control group. Statistical analyses were done using Stata 9 software. 
 
5.3 Results  
 
The observed genotype frequencies for CCR2-V64I polymorphism in the controls 
deviated from Hardy-Weinberg equilibrium (P = 0.001) (data not shown here). This 
could be due to the fact the our controls were not a randomly chosen population 
rather handpicked in a 3:1 matched ratio to the cases on decade of age, ethnic group 
and area of residence (urban/rural). Genotyping data for CCR2-V64I polymorphism 
was obtained on 1378 of the 1432 control specimens. The frequency of CCR2-64I 
variant was 63% in black cases and 24% in the black controls and 63% in cases of 
mixed-ancestry and 21% in mixed-ancestry controls. A statistically significant, 
association was found with CCR2-64I variant (P = 0.001) and cervical cancer cases 














Table 5.1  - Counts (n), frequencies (%) and association statistics for CCR2-V64I 
genotypes for cases and controls.  
 
 
 Controls (n = 1378)  Cases (n = 446) 
Genotype-cervical cancer 
association, adjusted for 
ethnicity and smoking  
Black 




1073 (n = 
78)  
Black 106 
(n = 24) 
Mixed-
ancestry 
340 (n = 
76) 
Genotypes n (%) n (%)  n (%) n (%) P-value OR (95% CI) 
CCR2 G→A       
GG 189 (62) 704 (66)  24 (23) 78 (23) - 1 
AG 112 (37) 356 (33)  81 (76) 255 (75) 0.001 6.22 (4.85-7.97) 
AA 4 (1) 13 (1)  1 (1) 7 (2) 0.002 3.99 (1.68-9.50) 
        
AG + AA  116 (38) 369 (34)  82 (77) 262 (77) 0.001 6.14 (4.79-7.86) 
                
 
 
P-values and OR (95% confidence intervals) are for test of genotype association with cervix cancer 
risk, adjusted for ethnicity and smoking. Cases = Women with cancer of the cervix (ICC), Controls = 
Women without cancer of the cervix. 
 
 
When the SIL positive (LSIL and HSIL positive) controls (n = 91) were compared 
with the invasive cervical cancer cases (n = 446) for CCR2-V64I polymorphism, a 
statistically significant association was found with the presence of CCR2-64I variant 



















Table 5.2  - Association statistics for CCR2-V64I genotypes for ICC compared with 





controls (n = 91)  Cases (n = 446) 
Genotype-cervical cancer 
association, adjusted for 











Genotypes n (%) n (%)  n (%) n (%) P-value OR (95% CI) 
CCR2 G→A       
GG 21 (68) 40 (66)  24 (23) 78 (23) - 1 
AG 9 (29) 19 (32)  81 (76) 255 (75) 0.001 7.18 (4.35-11.87) 
AA 1 (3) 1 (2)  1 (1) 7 (2) 0.300 2.32 (0.47-11.36) 
        
AG + AA  10 (32) 20 (33)  82 (77) 262 (77) 0.001 6.86 (4.19-11.21) 
                
 
 
Cases = Women with cancer of the cervix (ICC), SIL positive controls = Women without cancer of 
the cervix (ICC) but positive for LSIL and HSIL by pap smear test. 
 
 
Since the association was found with cancer it was then determined if the same 
association could be observed in precancers within the control group. The 
association of CCR2-V64I polymorphism with abnormal cytology and HSIL status 
was investigated only in the control group as the controls represent the larger South-
African population. Abnormal cytology was not found to be associated (P = 0.437) 























Normal cytology (n 
= 1070)  
Abnormal cytology  
(n = 185) 
Genotype-abnormal cytology 
association, adjusted for 











Genotypes n (%) n (%)  n (%) n (%) P-value OR (95% CI) 
CCR2 G→A       
GG 124 (59) 563 (66)  45 (70) 78 (64) - 1 
AG 84 (40) 287 (33)  17 (27) 40 (33) 0.290 0.83 (0.59-1.17) 
AA 2 (1) 10 (1)  2 (3) 3 (3) 0.134 2.28 (0.78-6.69) 
        
AG + AA  86 (41) 297 (35)  19 (30) 43 (36) 0.437 0.88 (0.63-1.22) 
                
 
Abnormal cytology = Positive for pap smear test (i.e. positive for ASCUS + positive for LSIL + 
positive for HSIL), Normal cytology = Negative for pap smear test. 
 
 
Comparing only the HSIL positive samples with all the normal cytology samples 
also did not show any significant association (P = 0.157) in controls adjusted for 
























Normal cytology (n 
= 1070)  
HSIL positive  
(n = 45) 
Genotype-HSIL association, 












Genotypes n (%) n (%)  n (%) n (%) P-value OR (95% CI) 
CCR2 G→A       
GG 124 (59) 563 (66)  12 (75) 21 (72) - 1 
AG 84 (40) 287 (33)  4 (25) 8 (28) 0.190 0.64 (0.32-1.25) 
AA 2 (1) 10 (1)  0 (0) 0 (0) - - 
        
AG + AA  86 (41) 297 (35)  4 (30) 8 (28) 0.157 0.61 (0.31-1.21) 
 
HSIL positive = Positive for HSIL by pap smear test, Normal cytology = Negative for pap smear test. 
 
5.4 Discussion  
 
Polymorphisms in the CCR2 gene that alters the macrophage recruitment have been 
reported to influence a number of diseases including  AIDS (Doms and Peiper, 
1997;Ioannidis et al., 2001;Mulherin et al., 2003;Smith et al., 1997), multiple 
sclerosis (Miyagishi et al., 2003), breast cancer (Zafiropoulos et al., 2004), carotid 
atherosclerosis (Nyquist et al., 2009) and renal transplant rejection (Omrani et al., 
2008). This polymorphism has also been associated with cervical cancer in two 
different populations (Coelho et al., 2005;Coelho et al., 2007;Ivansson et al., 
2007a;Zheng et al., 2006). 
 
Persistent HPV infection of epithelial cells is necessary for the carcinogenesis of the 
uterine cervix, but not all HPV-infected cervical lesions progress to cervical cancer. 
Chemokines are regarded as an important cofactor in the progression of the cervical 














We are the first to study the frequency of the CCR2-V64I polymorphism in an 
indigenous black African as well as in a mixed-ancestry population. We found a 
statistically significant association of CCR2-64I variant (P = 0.001) with cervical 
cancer in black African and mixed-ancestry women adjusted for ethnicity and 
smoking. Our data suggests that women carrying A allele (P = 0.001, OR (95% CI) = 
6.14 (4.79-7.86)) and A/A genotype (P = 0.002, OR (95% CI) = 3.99 (1.68-9.50)) at 
position 190 of the CCR2 gene have an increased risk of cervical cancer compared to 
women carrying the G variant. When the controls with SIL were compared with 
cervical cancer cases, it was found that CCR2-64I carriers are at greater risk of 
developing cervical cancer (P = 0.001, OR (95% CI) = 6.86 (4.19-11.21)) from SIL.  
The analysis of CCR2-V64I genotypes in control women with abnormal cytology (P 
= 0.437) and HSIL (P = 0.157) did not show any statistically significant association. 
However, the tendencies of the ORs for the above mentioned groups point towards a 
protective effect of the CCR2-64I variant in women with abnormal cytology (OR 
(95% CI) = 0.88 (0.63-1.22)) and HSIL (OR (95% CI) = 0.61 (0.31-1.21)) compared 
to women with normal cytology. 
 
Our results showing a susceptible effect of the CCR2-64I variant to cervical cancer 
(comparing controls without cancer of the cervix with controls SIL) are conflicting 
with reports showing a protective effect of this variant for cervical cancer by two 
other groups (Coelho et al., 2005;Ivansson et al., 2007a). Also our data showing no 
association of CCR2-64I variant with HSIL when compared to individuals with 
normal cytology, do not match Coelho et. al. (Coelho et al., 2007) who reported an 













due to one or several factors, including the difference in ethnic origin of the 
population studied the difference in sample size and high percentage of the mutant 
allele (CCR2-64I) in our population. The Portuguese population had a frequency of 
12.2% for the CCR264I variant, the Swedish population had a frequency of 13%, 
whereas in our population the frequency was much higher, (24% in black Africans 
and 21% in mixed-ancestry). The fact that we did not find any association with 
abnormal cytology or HSIL in the control group but found a susceptible effect with 
cervical cancer suggests that CCR2-64I variant is not associated with susceptibility 
to HPV infection or HSIL in our population but increases the risk of ICC at a later 





Figure 5.2  - A schematic diagram showing the susceptible effect of CCR2-64I variant 
during development of ICC. 
 
Our results showing no association of CCR2-64I variant with HPV infection with 
tendencies of the ORs toward a protective effect are in line with Zheng B et. al 
(Zheng et al., 2006) who did not find any association of CCR2-64I but observed 
similar ORs (OR (95% CI) = 0.006-1.92) as reported by us. 
 
Not much is known about the immune response to HPV-infected epithelial cells as 
HPV typically does not elicit strong local or systemic immune responses. MCP-1 













chemokines that induces recruitment of macrophages in tumours including cervical 
cancer (Vicari and Caux, 2002). Recruitment and activation of macrophages is a vital 
process for the inflammatory response of the human body. Though macrophages 
display tumor cytotoxicity, tumor-associated macrophages (TAMs) mainly have 
protumour functions (Mantovani et al., 1992) and help in tumor angiogenesis. 
Increased expression of MCP-1 recruits more macrophages which speed up the 
process of tumour destruction or progression depending upon the type of 
macrophages recruited. After the infection of epithelial cells by HPV, the MCP-1 
expression decreases from LSIL to HSIL and increases again from HSIL to ICC 
(Riethdorf et al., 1996). Tumor cells have been reported with high levels of MCP-1 
expression (Kleine-Lowinski et al., 1999). Macrophages which are recruited by 
MCP-1 chemokine, express CCR2 on their cell-surface. The CCR2-64I variant is 
associated with increased expression of CCR2A (due to increased stability of 
CCR2A) on the cell-surface of monocytes. This increases the attraction of 
monocytes to tumour cells producing MCP-1. In early stages of infection, the 
increased recruitment of monocytes results in more macrophages and associated cells 
(DC and NK cells) converging on the developing tumours to destroy the progressing 
tumours cells. Therefore, increased expression of CCR2 receptors results in 
increased recruitment of macrophages and possibly faster destruction of a developing 
tumour. Thus the CCR2-64I variant might be associated with reduced risk of 
developing cancer in the early phase. Our results with HPV-infected individuals do 
point toward a reduced risk of CCR2-64I with abnormal cytology and HSIL 
positivity when compared to individuals with normal cytology (according to the 














However, once the tumour cells evade the immune system, the macrophages that are 
recruited towards elimination of the tumour switch to TAMs (Lamagna et al., 
2006;Lin and Pollard, 2007). The increased stability of CCR2A due to CCR2-64I 
variant sustains the tumours by continuously recruiting TAMs that support tumour 
angiogenesis. It is not known when this switch from tumour cytotoxic macrophages 
to TAMs occurs during the development of cervical cancer. We hypothesize that the 
switch occurs during early phase of HSIL. Thus the CCR2-64I variant would be 
associated with increased risk of cancer in the later stage of tumour development (in 
this situation after progressing to HSIL) when compared to the CCR2-64V variant 
which is associated with less stable CCR2A stability and expression. 
 
CCR2 gene lies within 10kbp from CCR5 and are in strong LD with CCR5. CCR5 
protein is also known to play important roles in inflammatory responses to infection. 
It has a crucial role in chemotaxis of Th
1
 cells and CD8
+
 effector T cells (Zaitseva et 
al., 1998). The possibility that the observed genetic association in the CCR2 gene 
could be linked to the CCR5 gene or acting through strong LD by another modifier 
gene in CCR5 cannot be ruled out. 
 
5.5 Conclusion  
Our study showed a significant association of CCR2-V64I polymorphism with 
cervical cancer, but did not show any association with HPV infection or HSIL. 
CCR2-64I variant showed an increased risk of cervical cancer but not with infection 
by HPV. This implies that this mutation is associated with a late event in the 
progression to cervical cancer. Further studies are needed with patients in different 
















Genetic diseases are divided into monogenic and complex disorders. Monogenic or 
Mendelian disorders are caused by a single mutation or more than one mutation in a 
single gene. Complex diseases, also called non-Mendelian disorders are 
multifactorial and highly complex in nature. Complex disorders can be caused by 
both environmental and genetic risk factors interacting in a complicated pattern to 
produce a particular disorder. Many common diseases are multifactorial such as 
diabetes, hypertension, allergy, cancer, cardiovascular and psychiatric diseases.  
 
Human-disease gene-identification was mainly limited to monogenic disorders prior 
to 1980. The invention of polymerase chain reaction (PCR) and mutation screening 
technologies along with the Human Genome Project (HUGO) to identify human 
protein coding genes (Collins FS, 2004;Lander et al., 2001) and the International 
HapMap Project to identify the human genetic variation (Frazer et al., 2007;Gibbs 
AR, 2005) have moved the field much faster since then. Most of the monogenic 
diseases are now mapped with their causative gene being identified. On the other 
hand identifying risk genes in complex diseases are much more difficult as there are 
many factors involved, including different causative genes influencing with different 
degrees of severeity. The complex interaction between different genes and between 
genes and the environmental plays a critical role in the outcome of a complex 
disorders such as cancer. The present day medical genetics research has moved more 













causative agents and their pattern of interaction with each other to produce a 
particular disease. 
 
Cervical cancer, a complex and multifactorial disease which is mainly caused by 
persistent infection with oncogenic types of Human Papillomavirus (HPV) exhibits 
differential risk in individuals due to the combination of different risk factors mainly 
genetic and environmental. In order to estimate or measure risk to develop cervical 
cancer, HPV infection is included as a primary causative agent and outcome of 
disease is dependent on interactions with other infectious agents such as HSV-2, the 
variable host genetics involving genes that play major role in immune surveillance, 
programmed cell death and regulation of cell cycle. It is well established that 
individual immune response plays a vital role in protection to different viral 
infections and also to cancer. Host genes play a key role in shaping an individuals 
immune response that can eliminate a viral infection from the body or stop the 
growth of the tumourous cells. 
 
The presence of HSV-2 and HPV infections is a significant risk to developing 
cervical cancer compared to infection with only HPV. The interaction between HSV-
2 and high-risk HPV types (mainly HPV-16 and 18) has been suggested to play an 
important role in the development of cervical cancer (Jones, 1995). Several 
epidemiological studies have associated HSV-2 infection to an increased incidence 
of cervical cancer (Jones, 1995). 
 
HSV-2 genome is made up of two distinct and morphologically separate 













tumour cells. Studies have demonstrated the ability of mtrIII to co-operate with 
HPV-16 and HPV-18 to transform human fibroblasts or keratinocytes. PCR analysis 
of the transformed cells shows consistent presence of HSV-2 DNA sequences 
(Dhanwada et al., 1992). Human keratinocytes that are immortalized with HPV-16 
(FELP) or HPV-18 (FEA) infected with plasmids containing mtrIII results in a 
higher saturation density cell lines. Only FELP cells (not FEA) developed into 
benign lesions in nu/nu mice (Dhanwada et al., 1993). Genital epithelial cells 
containing HPV-16 sequences have been shown to convert into tumourigenic 
squamous cell carcinomas by plasmids containing mtrII (DiPaolo et al., 1990). 
Follow-up investigation did not find HSV-2 DNA sequences, however, the 
oncogenic potential of HSV-2 was not lost. These studies support the fact that 
infection with high-risk HPV types is necessary but not sufficient for cervical cancer 
and HSV-2 infection may play a role in the outcome of the disease in association 
with HPV. 
 
Apoptosis is one of the most important mechanisms of the human immune system to 
control viral infections and malignant cells. It is a highly programmed process of cell 
suicide. Apoptosis induced in viral infected cells helps to eliminate a viral infection. 
On the other hand, apoptosis induced in malignant cells helps to restrict uncontrolled 
growth of the cancerous cells. Therefore, appropriate regulation of apoptotic process 
is extremely crucial in controlling a viral infection as well as spread of a cancer. The 
signals produced by the cell-surface death receptor Fas together with FasL activate 
caspase-8 which triggers apoptosis. Alterations in the genes involved in this cell 
death pathway are bound to manipulate the regulations of the process of apoptosis 













Hence, functional polymorphisms at genes encoding Fas, FasL and caspase-8 fall 
under scrutiny in understanding the risk factors contributing to persistent HPV 
infection and different stages of pre-cancerous lesions leading to cervical cancer. 
CASP8 -652 6N del/del genotype significantly increased the risk of abnormal 
cytology in South African women of black and mixed-ancestry origin. The same 
CASP8 genotype also increased the risk of high-risk HPV infection in black African 
individuals. 
 
FasR-1377A allele and FasR-1377/FasR-670AG haplotype significantly reduced the 
risk of HSV-2 infection with a mechanism hitherto unknown. To our knowledge, this 
is the first non-HLA host genetic association of HSV-2 infection reported till now. 
 
Recruitment and activation of macrophages is an important process of host immune 
response against tumour development. The macrophages play a dual role in 
development of cancer from the early stages of very few pre-cancerous cells. At the 
beginning of pre-cancerous lesions macrophages have tumour-cytotoxic 
charastiristics which helps to eliminate the cancerous cells. At later stages when 
tumour cells have evaded the immune system the macrophages switch to tumour-
angiogenesis and aid the tumour to grow faster. CCR2 is a major receptor for MCP-1 
that recruits macrophages to tumour cells. Altered CCR2 expression due to 
functional polymorphism on the CCR2 gene would influence the recruitment of 
macrophages thus affecting the growth of the tumour cells. CCR264I variant 
significantly increased the risk of cervical cancer but did no affect the risk of HPV 













cervical cancer. This polymorphism may be used as a target to manage cervical 
cancer. 
 
To summarise our findings on host genetic determinants of HPV infection, and 
cervical cancer South African women; different genes influence HPV infection and 
pre-cancerous lesions leading to cervical cancer differently. Figure 6.1 captures the 






Fig. 6.1: A schematic diagram showing the role of Fas, FasL, CASP8 and CCR2 gene 
polymorphisms during development of ICC 
 
This is the first time the roles of Fas, FasL, CASP8 and CCR2 gene polymorphisms 
have been studied in HPV infection and cervical cancer in indigenous black and 
mixed-ancestry African population. Our finding of an association of a Fas 
polymorphism with HSV-2 infection is a first time non-HLA host genetic 
determinants for HSV-2 infection have been reported. 
 
The limitations of these studies can also not be ignored. Although the strength of the 
studies lie in selection of a well matched cohort for cervical cancer, it should be 
acknowledged that the study was not initially designed to investigate host genetics. 












It is well known that a genetically mixed group is never an ideal population to do 
genetic studies. Though the black African group is a homogenous group, the mixed-
ancestry population is mixed with people from diverse geographical locations 
varying from Asia to Africa and Europe. Hence the chance of finding a not so strong 
genetic modifier becomes less probable for a mixed group. The study finding 
association between genotypes and HSV-2 infection deals with the control subjects 
for the cervical cancer case-control cohort. This is again a limitation, as the HSV-2 
study lacked a well designed cohort with perfectly matched cases and controls as in 
all the other cervical cancer studies. The possibility of false positive values from 
genotyping results is always a concern. However, the large sample size used in this 
study might have reduced the effect of false positive values. 
 
Keeping these limitations in mind, it is important to further investigate the 
polymorphisms investigated in this thesis in a homogenous and well matched case-
control cohort. Probably an SNP tagging approach to a wide range of candidate 
genes or a whole genome scan would drive the search for the causative genetic effect 
to cervical cancer faster. The host genetics research of complex and infectious 
diseases have created a lot of interest in the recent past. This is important in better 
understanding of the infectious disease biology, the host-virus interaction and the 
way the host responds to that. Further research in this field will also enable the 
researchers to design genetic markers for diagnostic purposes for infectious diseases. 
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